drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00352 | DB08864 | 482 | 786 | [
"DDInter1814",
"DDInter1595"
] | Tioguanine | Rilpivirine | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. | Moderate | 1 | [
[
[
482,
24,
786
]
],
[
[
482,
21,
28722
],
[
28722,
60,
786
]
],
[
[
482,
24,
522
],
[
522,
24,
786
]
],
[
[
482,
63,
1560
],
[
1560,
24,
786
]
],
[
[
482,
25,
770
],
[
770,
24,
786
]
],
[
[
482,
24,
971
],
[
971,
63,
786
]
],
[
[
482,
24,
1154
],
[
1154,
25,
786
]
],
[
[
482,
25,
1377
],
[
1377,
25,
786
]
],
[
[
482,
25,
1011
],
[
1011,
64,
786
]
],
[
[
482,
24,
351
],
[
351,
64,
786
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
]
] | Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Rilpivirine (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Rilpivirine
Tioguanine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rilpivirine
Tioguanine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Rilpivirine
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rilpivirine |
DB00889 | DB01209 | 1,133 | 1,359 | [
"DDInter840",
"DDInter531"
] | Granisetron | Dezocine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
1133,
24,
1359
]
],
[
[
1133,
64,
234
],
[
234,
1,
1359
]
],
[
[
1133,
40,
85
],
[
85,
24,
1359
]
],
[
[
1133,
1,
19
],
[
19,
24,
1359
]
],
[
[
1133,
25,
1264
],
[
1264,
24,
1359
]
],
[
[
1133,
64,
1166
],
[
1166,
24,
1359
]
],
[
[
1133,
24,
1662
],
[
1662,
63,
1359
]
],
[
[
1133,
24,
770
],
[
770,
24,
1359
]
],
[
[
1133,
25,
1629
],
[
1629,
64,
1359
]
],
[
[
1133,
25,
593
],
[
593,
25,
1359
]
]
] | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
],
[
"Pentazocine",
"{u} (Compound) resembles {v} (Compound)",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} (Compound) resembles {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} (Compound) resembles {v} (Compound)",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dezocine"
]
]
] | Granisetron may lead to a major life threatening interaction when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Granisetron (Compound) resembles Atropine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron (Compound) resembles Hyoscyamine (Compound) and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Granisetron may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Dezocine
Granisetron may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Dezocine |
DB01044 | DB06723 | 246 | 115 | [
"DDInter809",
"DDInter58"
] | Gatifloxacin | Aluminum hydroxide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
246,
24,
115
]
],
[
[
246,
21,
28643
],
[
28643,
60,
115
]
],
[
[
246,
64,
870
],
[
870,
23,
115
]
],
[
[
246,
63,
355
],
[
355,
23,
115
]
],
[
[
246,
25,
401
],
[
401,
23,
115
]
],
[
[
246,
23,
60
],
[
60,
23,
115
]
],
[
[
246,
40,
1176
],
[
1176,
24,
115
]
],
[
[
246,
25,
1213
],
[
1213,
24,
115
]
],
[
[
246,
24,
428
],
[
428,
63,
115
]
],
[
[
246,
63,
1096
],
[
1096,
24,
115
]
]
] | [
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
]
] | Gatifloxacin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Gatifloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Gatifloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Gatifloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Gatifloxacin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide |
DB00404 | DB00835 | 523 | 100 | [
"DDInter54",
"DDInter245"
] | Alprazolam | Brompheniramine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
523,
24,
100
]
],
[
[
523,
24,
832
],
[
832,
24,
100
]
],
[
[
523,
24,
649
],
[
649,
63,
100
]
],
[
[
523,
63,
1594
],
[
1594,
24,
100
]
],
[
[
523,
6,
8374
],
[
8374,
45,
100
]
],
[
[
523,
1,
1216
],
[
1216,
24,
100
]
],
[
[
523,
1,
1418
],
[
1418,
63,
100
]
],
[
[
523,
40,
1408
],
[
1408,
24,
100
]
],
[
[
523,
64,
475
],
[
475,
24,
100
]
],
[
[
523,
24,
662
],
[
662,
35,
100
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Loxapine"
],
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
]
] | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound)
Alprazolam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine |
DB01319 | DB06626 | 34 | 263 | [
"DDInter777",
"DDInter147"
] | Fosamprenavir | Axitinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations. | Major | 2 | [
[
[
34,
25,
263
]
],
[
[
34,
63,
1215
],
[
1215,
23,
263
]
],
[
[
34,
24,
101
],
[
101,
23,
263
]
],
[
[
34,
64,
392
],
[
392,
24,
263
]
],
[
[
34,
25,
1593
],
[
1593,
63,
263
]
],
[
[
34,
63,
1324
],
[
1324,
24,
263
]
],
[
[
34,
24,
214
],
[
214,
63,
263
]
],
[
[
34,
25,
1250
],
[
1250,
24,
263
]
],
[
[
34,
63,
1220
],
[
1220,
25,
263
]
],
[
[
34,
24,
913
],
[
913,
64,
263
]
]
] | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
]
] | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Fosamprenavir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Fosamprenavir may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Fosamprenavir may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Axitinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Axitinib |
DB00352 | DB00641 | 482 | 467 | [
"DDInter1814",
"DDInter1675"
] | Tioguanine | Simvastatin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as [pravastatin] and [rosuvastatin] which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.[A181424,A181460] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins. | Moderate | 1 | [
[
[
482,
24,
467
]
],
[
[
482,
6,
7129
],
[
7129,
57,
467
]
],
[
[
482,
21,
28722
],
[
28722,
60,
467
]
],
[
[
482,
24,
800
],
[
800,
63,
467
]
],
[
[
482,
63,
367
],
[
367,
24,
467
]
],
[
[
482,
64,
1057
],
[
1057,
24,
467
]
],
[
[
482,
24,
134
],
[
134,
24,
467
]
],
[
[
482,
25,
375
],
[
375,
63,
467
]
],
[
[
482,
23,
839
],
[
839,
24,
467
]
],
[
[
482,
24,
1668
],
[
1668,
25,
467
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} (Compound) binds {v} (Gene)",
"HPRT1"
],
[
"HPRT1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
]
]
] | Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Simvastatin (Compound)
Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Simvastatin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide may lead to a major life threatening interaction when taken with Simvastatin |
DB00290 | DB01042 | 329 | 1,307 | [
"DDInter219",
"DDInter1144"
] | Bleomycin | Melphalan | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | Moderate | 1 | [
[
[
329,
24,
1307
]
],
[
[
329,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
329,
21,
28766
],
[
28766,
60,
1307
]
],
[
[
329,
23,
956
],
[
956,
62,
1307
]
],
[
[
329,
23,
739
],
[
739,
23,
1307
]
],
[
[
329,
24,
322
],
[
322,
23,
1307
]
],
[
[
329,
62,
1176
],
[
1176,
23,
1307
]
],
[
[
329,
63,
66
],
[
66,
24,
1307
]
],
[
[
329,
24,
1186
],
[
1186,
63,
1307
]
],
[
[
329,
24,
869
],
[
869,
24,
1307
]
]
] | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
],
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
]
] | Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Bleomycin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Melphalan (Compound)
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Melphalan |
DB00377 | DB00582 | 1,494 | 1,622 | [
"DDInter1382",
"DDInter1946"
] | Palonosetron | Voriconazole | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Moderate | 1 | [
[
[
1494,
24,
1622
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
1494,
21,
28957
],
[
28957,
60,
1622
]
],
[
[
1494,
23,
112
],
[
112,
62,
1622
]
],
[
[
1494,
24,
823
],
[
823,
63,
1622
]
],
[
[
1494,
24,
1424
],
[
1424,
24,
1622
]
],
[
[
1494,
63,
521
],
[
521,
24,
1622
]
],
[
[
1494,
25,
1264
],
[
1264,
63,
1622
]
],
[
[
1494,
24,
1213
],
[
1213,
64,
1622
]
],
[
[
1494,
25,
351
],
[
351,
64,
1622
]
]
] | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
]
]
] | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Palonosetron (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Palonosetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Voriconazole
Palonosetron may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Voriconazole |
DB00835 | DB11642 | 100 | 938 | [
"DDInter245",
"DDInter1480"
] | Brompheniramine | Pitolisant | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
100,
24,
938
]
],
[
[
100,
1,
28
],
[
28,
24,
938
]
],
[
[
100,
63,
1233
],
[
1233,
24,
938
]
],
[
[
100,
24,
820
],
[
820,
24,
938
]
],
[
[
100,
74,
662
],
[
662,
24,
938
]
],
[
[
100,
35,
272
],
[
272,
24,
938
]
],
[
[
100,
1,
28
],
[
28,
63,
600
],
[
600,
24,
938
]
],
[
[
100,
63,
1233
],
[
1233,
24,
820
],
[
820,
24,
938
]
],
[
[
100,
24,
820
],
[
820,
62,
112
],
[
112,
23,
938
]
],
[
[
100,
74,
662
],
[
662,
1,
28
],
[
28,
24,
938
]
]
] | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitolisant"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
]
] | Brompheniramine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine (Compound) resembles Chlorpheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant |
DB00694 | DB00850 | 51 | 1,630 | [
"DDInter485",
"DDInter1432"
] | Daunorubicin | Perphenazine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
51,
24,
1630
]
],
[
[
51,
63,
252
],
[
252,
40,
1630
]
],
[
[
51,
24,
673
],
[
673,
40,
1630
]
],
[
[
51,
64,
684
],
[
684,
40,
1630
]
],
[
[
51,
6,
7950
],
[
7950,
45,
1630
]
],
[
[
51,
7,
6448
],
[
6448,
46,
1630
]
],
[
[
51,
18,
2958
],
[
2958,
46,
1630
]
],
[
[
51,
18,
2183
],
[
2183,
57,
1630
]
],
[
[
51,
7,
6168
],
[
6168,
57,
1630
]
],
[
[
51,
21,
29232
],
[
29232,
60,
1630
]
]
] | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) upregulates {v} (Gene)",
"CTSD"
],
[
"CTSD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"JADE2"
],
[
"JADE2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) upregulates {v} (Gene)",
"IGFBP3"
],
[
"IGFBP3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
]
] | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Perphenazine (Compound)
Daunorubicin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Perphenazine (Compound)
Daunorubicin (Compound) upregulates CTSD (Gene) and CTSD (Gene) is upregulated by Perphenazine (Compound)
Daunorubicin (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Perphenazine (Compound)
Daunorubicin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Perphenazine (Compound)
Daunorubicin (Compound) upregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Perphenazine (Compound)
Daunorubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Perphenazine (Compound) |
DB00582 | DB00959 | 1,622 | 1,486 | [
"DDInter1946",
"DDInter1191"
] | Voriconazole | Methylprednisolone | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Major | 2 | [
[
[
1622,
25,
1486
]
],
[
[
1622,
25,
175
],
[
175,
40,
1486
]
],
[
[
1622,
24,
167
],
[
167,
1,
1486
]
],
[
[
1622,
63,
251
],
[
251,
1,
1486
]
],
[
[
1622,
24,
303
],
[
303,
40,
1486
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1486
]
],
[
[
1622,
21,
28997
],
[
28997,
60,
1486
]
],
[
[
1622,
24,
1674
],
[
1674,
23,
1486
]
],
[
[
1622,
24,
1148
],
[
1148,
62,
1486
]
],
[
[
1622,
25,
455
],
[
455,
23,
1486
]
]
] | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
]
] | Voriconazole may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Methylprednisolone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Methylprednisolone (Compound)
Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylprednisolone (Compound)
Voriconazole (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Voriconazole may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone |
DB00486 | DB00754 | 1,614 | 157 | [
"DDInter1253",
"DDInter696"
] | Nabilone | Ethotoin | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Moderate | 1 | [
[
[
1614,
24,
157
]
],
[
[
1614,
24,
759
],
[
759,
40,
157
]
],
[
[
1614,
24,
499
],
[
499,
1,
157
]
],
[
[
1614,
21,
28763
],
[
28763,
60,
157
]
],
[
[
1614,
24,
1264
],
[
1264,
63,
157
]
],
[
[
1614,
24,
1219
],
[
1219,
24,
157
]
],
[
[
1614,
63,
128
],
[
128,
24,
157
]
],
[
[
1614,
40,
530
],
[
530,
24,
157
]
],
[
[
1614,
24,
759
],
[
759,
40,
11368
],
[
11368,
40,
157
]
],
[
[
1614,
24,
499
],
[
499,
1,
11368
],
[
11368,
40,
157
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
],
[
"Phensuximide",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Glutethimide"
],
[
"Glutethimide",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
],
[
"Phensuximide",
"{u} (Compound) resembles {v} (Compound)",
"Glutethimide"
],
[
"Glutethimide",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
]
] | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Ethotoin (Compound)
Nabilone (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Ethotoin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Glutethimide (Compound) and Glutethimide (Compound) resembles Ethotoin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Glutethimide (Compound) and Glutethimide (Compound) resembles Ethotoin (Compound) |
DB00762 | DB00834 | 613 | 932 | [
"DDInter973",
"DDInter1215"
] | Irinotecan | Mifepristone | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Major | 2 | [
[
[
613,
25,
932
]
],
[
[
613,
6,
7524
],
[
7524,
45,
932
]
],
[
[
613,
7,
6314
],
[
6314,
46,
932
]
],
[
[
613,
18,
10699
],
[
10699,
57,
932
]
],
[
[
613,
7,
4071
],
[
4071,
57,
932
]
],
[
[
613,
21,
28762
],
[
28762,
60,
932
]
],
[
[
613,
63,
1101
],
[
1101,
23,
932
]
],
[
[
613,
63,
597
],
[
597,
24,
932
]
],
[
[
613,
24,
86
],
[
86,
63,
932
]
],
[
[
613,
25,
976
],
[
976,
63,
932
]
]
] | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} (Compound) upregulates {v} (Gene)",
"TLR4"
],
[
"TLR4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} (Compound) upregulates {v} (Gene)",
"PNP"
],
[
"PNP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
]
] | Irinotecan (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Irinotecan (Compound) upregulates TLR4 (Gene) and TLR4 (Gene) is upregulated by Mifepristone (Compound)
Irinotecan (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Mifepristone (Compound)
Irinotecan (Compound) upregulates PNP (Gene) and PNP (Gene) is downregulated by Mifepristone (Compound)
Irinotecan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Irinotecan may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone |
DB01175 | DB12141 | 318 | 971 | [
"DDInter672",
"DDInter817"
] | Escitalopram | Gilteritinib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Major | 2 | [
[
[
318,
25,
971
]
],
[
[
318,
62,
112
],
[
112,
23,
971
]
],
[
[
318,
64,
485
],
[
485,
24,
971
]
],
[
[
318,
25,
823
],
[
823,
63,
971
]
],
[
[
318,
25,
820
],
[
820,
24,
971
]
],
[
[
318,
24,
1409
],
[
1409,
24,
971
]
],
[
[
318,
24,
283
],
[
283,
63,
971
]
],
[
[
318,
62,
597
],
[
597,
24,
971
]
],
[
[
318,
63,
1559
],
[
1559,
24,
971
]
],
[
[
318,
23,
159
],
[
159,
63,
971
]
]
] | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
]
] | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Escitalopram may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib |
DB00197 | DB09061 | 1,324 | 1,627 | [
"DDInter1881",
"DDInter284"
] | Troglitazone | Cannabidiol | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals . Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), (CBDV), and (THCV) that can be found within the medical cannabis . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body . Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety. In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574]. CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer . In April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome . On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. | Moderate | 1 | [
[
[
1324,
24,
1627
]
],
[
[
1324,
24,
723
],
[
723,
23,
1627
]
],
[
[
1324,
24,
351
],
[
351,
62,
1627
]
],
[
[
1324,
24,
888
],
[
888,
24,
1627
]
],
[
[
1324,
24,
1613
],
[
1613,
63,
1627
]
],
[
[
1324,
63,
1560
],
[
1560,
24,
1627
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
1627
]
],
[
[
1324,
25,
1510
],
[
1510,
25,
1627
]
],
[
[
1324,
24,
723
],
[
723,
24,
760
],
[
760,
62,
1627
]
],
[
[
1324,
24,
609
],
[
609,
63,
723
],
[
723,
23,
1627
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Troglitazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol |
DB01075 | DB08883 | 1,376 | 1,597 | [
"DDInter569",
"DDInter1428"
] | Diphenhydramine | Perampanel | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. | Moderate | 1 | [
[
[
1376,
24,
1597
]
],
[
[
1376,
74,
100
],
[
100,
24,
1597
]
],
[
[
1376,
24,
649
],
[
649,
24,
1597
]
],
[
[
1376,
63,
104
],
[
104,
24,
1597
]
],
[
[
1376,
35,
272
],
[
272,
24,
1597
]
],
[
[
1376,
24,
407
],
[
407,
63,
1597
]
],
[
[
1376,
74,
100
],
[
100,
24,
649
],
[
649,
24,
1597
]
],
[
[
1376,
24,
649
],
[
649,
63,
100
],
[
100,
24,
1597
]
],
[
[
1376,
63,
104
],
[
104,
63,
100
],
[
100,
24,
1597
]
],
[
[
1376,
35,
272
],
[
272,
74,
100
],
[
100,
24,
1597
]
]
] | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
]
] | Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel |
DB00434 | DB00782 | 13 | 1,123 | [
"DDInter459",
"DDInter1535"
] | Cyproheptadine | Propantheline | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
13,
24,
1123
]
],
[
[
13,
6,
7992
],
[
7992,
45,
1123
]
],
[
[
13,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
13,
24,
551
],
[
551,
23,
1123
]
],
[
[
13,
24,
768
],
[
768,
63,
1123
]
],
[
[
13,
63,
999
],
[
999,
24,
1123
]
],
[
[
13,
24,
684
],
[
684,
24,
1123
]
],
[
[
13,
25,
675
],
[
675,
24,
1123
]
],
[
[
13,
74,
695
],
[
695,
24,
1123
]
],
[
[
13,
35,
1405
],
[
1405,
63,
1123
]
]
] | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
]
] | Cyproheptadine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propantheline (Compound)
Cyproheptadine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may cause a minor interaction that can limit clinical effects when taken with Propantheline
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Cyproheptadine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Cyproheptadine (Compound) resembles Clozapine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Cyproheptadine (Compound) resembles Cyclobenzaprine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline |
DB00374 | DB08907 | 1,061 | 1,344 | [
"DDInter1852",
"DDInter280"
] | Treprostinil | Canagliflozin | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
1061,
24,
1344
]
],
[
[
1061,
24,
549
],
[
549,
1,
1344
]
],
[
[
1061,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
1061,
24,
1445
],
[
1445,
24,
1344
]
],
[
[
1061,
24,
947
],
[
947,
63,
1344
]
],
[
[
1061,
63,
1245
],
[
1245,
24,
1344
]
],
[
[
1061,
1,
885
],
[
885,
24,
1344
]
],
[
[
1061,
25,
4
],
[
4,
24,
1344
]
],
[
[
1061,
23,
402
],
[
402,
24,
1344
]
],
[
[
1061,
35,
699
],
[
699,
24,
1344
]
]
] | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
],
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Treprostinil (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Riociguat and Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil may cause a minor interaction that can limit clinical effects when taken with Tadalafil and Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Treprostinil (Compound) resembles Nadolol (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB01070 | DB14012 | 1,098 | 349 | [
"DDInter558",
"DDInter253"
] | Dihydrotachysterol | Burosumab | A vitamin D that can be regarded as a reduction product of vitamin D2. | Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life . XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. Most children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain. Some adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss . | Major | 2 | [
[
[
1098,
25,
349
]
],
[
[
1098,
25,
1196
],
[
1196,
25,
349
]
],
[
[
1098,
64,
1041
],
[
1041,
25,
349
]
],
[
[
1098,
25,
1196
],
[
1196,
64,
1041
],
[
1041,
25,
349
]
],
[
[
1098,
64,
1041
],
[
1041,
25,
1196
],
[
1196,
25,
349
]
],
[
[
1098,
23,
1142
],
[
1142,
23,
1196
],
[
1196,
25,
349
]
],
[
[
1098,
64,
1041
],
[
1041,
64,
160
],
[
160,
25,
349
]
],
[
[
1098,
63,
359
],
[
359,
24,
1196
],
[
1196,
25,
349
]
],
[
[
1098,
23,
1142
],
[
1142,
62,
160
],
[
160,
25,
349
]
],
[
[
1098,
63,
690
],
[
690,
63,
160
],
[
160,
25,
349
]
]
] | [
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
],
[
"Orlistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
],
[
"Orlistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Burosumab"
]
]
] | Dihydrotachysterol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Burosumab
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Burosumab |
DB00738 | DB06335 | 485 | 761 | [
"DDInter1420",
"DDInter1646"
] | Pentamidine | Saxagliptin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
485,
24,
761
]
],
[
[
485,
6,
7524
],
[
7524,
45,
761
]
],
[
[
485,
21,
29226
],
[
29226,
60,
761
]
],
[
[
485,
24,
1491
],
[
1491,
63,
761
]
],
[
[
485,
24,
1630
],
[
1630,
24,
761
]
],
[
[
485,
63,
508
],
[
508,
24,
761
]
],
[
[
485,
25,
478
],
[
478,
24,
761
]
],
[
[
485,
64,
684
],
[
684,
24,
761
]
],
[
[
485,
25,
1154
],
[
1154,
63,
761
]
],
[
[
485,
64,
1101
],
[
1101,
25,
761
]
]
] | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saxagliptin"
]
]
] | Pentamidine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Pentamidine (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Saxagliptin (Compound)
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Saxagliptin |
DB00916 | DB01098 | 112 | 14 | [
"DDInter1202",
"DDInter1622"
] | Metronidazole | Rosuvastatin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] This is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.[A181409,A1793] However, the results of the SATURN trial concluded that despite this difference in potency, there was no difference in their effect on the progression of coronary atherosclerosis. Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as [ciclosporin], [gemfibrozil], and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.[F4649, F4652] | Moderate | 1 | [
[
[
112,
24,
14
]
],
[
[
112,
24,
671
],
[
671,
24,
14
]
],
[
[
112,
6,
8374
],
[
8374,
45,
14
]
],
[
[
112,
21,
29462
],
[
29462,
60,
14
]
],
[
[
112,
62,
600
],
[
600,
23,
14
]
],
[
[
112,
23,
1250
],
[
1250,
63,
14
]
],
[
[
112,
24,
1060
],
[
1060,
63,
14
]
],
[
[
112,
64,
126
],
[
126,
24,
14
]
],
[
[
112,
63,
268
],
[
268,
24,
14
]
],
[
[
112,
62,
322
],
[
322,
24,
14
]
]
] | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
]
] | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Metronidazole (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Rosuvastatin (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Metronidazole may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin |
DB01001 | DB06288 | 688 | 607 | [
"DDInter1632",
"DDInter77"
] | Salbutamol | Amisulpride | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys. | Moderate | 1 | [
[
[
688,
24,
607
]
],
[
[
688,
21,
29232
],
[
29232,
60,
607
]
],
[
[
688,
62,
112
],
[
112,
23,
607
]
],
[
[
688,
63,
1559
],
[
1559,
24,
607
]
],
[
[
688,
24,
1383
],
[
1383,
63,
607
]
],
[
[
688,
62,
870
],
[
870,
24,
607
]
],
[
[
688,
23,
1042
],
[
1042,
24,
607
]
],
[
[
688,
25,
351
],
[
351,
64,
607
]
],
[
[
688,
24,
401
],
[
401,
25,
607
]
],
[
[
688,
63,
1166
],
[
1166,
25,
607
]
]
] | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
]
] | Salbutamol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Salbutamol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Amisulpride
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Amisulpride
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Amisulpride |
DB00078 | DB04865 | 1,172 | 4 | [
"DDInter898",
"DDInter1335"
] | Ibritumomab tiuxetan | Omacetaxine mepesuccinate | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Major | 2 | [
[
[
1172,
25,
4
]
],
[
[
1172,
24,
496
],
[
496,
63,
4
]
],
[
[
1172,
24,
66
],
[
66,
24,
4
]
],
[
[
1172,
63,
1253
],
[
1253,
24,
4
]
],
[
[
1172,
25,
1468
],
[
1468,
63,
4
]
],
[
[
1172,
25,
1213
],
[
1213,
24,
4
]
],
[
[
1172,
25,
831
],
[
831,
25,
4
]
],
[
[
1172,
25,
1650
],
[
1650,
64,
4
]
],
[
[
1172,
64,
1432
],
[
1432,
25,
4
]
],
[
[
1172,
37,
1263
],
[
1263,
25,
4
]
]
] | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Indomethacin and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Bromfenac and Bromfenac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate |
DB01601 | DB12245 | 833 | 823 | [
"DDInter1089",
"DDInter1863"
] | Lopinavir | Triclabendazole | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
833,
24,
823
]
],
[
[
833,
63,
1010
],
[
1010,
24,
823
]
],
[
[
833,
24,
28
],
[
28,
24,
823
]
],
[
[
833,
25,
868
],
[
868,
25,
823
]
],
[
[
833,
64,
702
],
[
702,
25,
823
]
],
[
[
833,
1,
1327
],
[
1327,
25,
823
]
],
[
[
833,
25,
877
],
[
877,
64,
823
]
],
[
[
833,
63,
1010
],
[
1010,
23,
1247
],
[
1247,
23,
823
]
],
[
[
833,
24,
28
],
[
28,
24,
1612
],
[
1612,
24,
823
]
],
[
[
833,
63,
918
],
[
918,
62,
1247
],
[
1247,
23,
823
]
]
] | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
]
] | Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Lopinavir may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Lopinavir may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Lopinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Triclabendazole
Lopinavir may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Triclabendazole
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole |
DB00586 | DB01175 | 1,512 | 318 | [
"DDInter537",
"DDInter672"
] | Diclofenac | Escitalopram | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
1512,
24,
318
]
],
[
[
1512,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1512,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1512,
21,
29461
],
[
29461,
60,
318
]
],
[
[
1512,
24,
86
],
[
86,
23,
318
]
],
[
[
1512,
24,
1478
],
[
1478,
62,
318
]
],
[
[
1512,
64,
834
],
[
834,
24,
318
]
],
[
[
1512,
63,
1314
],
[
1314,
24,
318
]
],
[
[
1512,
24,
714
],
[
714,
24,
318
]
],
[
[
1512,
62,
752
],
[
752,
24,
318
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Dysmenorrhoea"
],
[
"Dysmenorrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Diclofenac (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Diclofenac (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrhoea (Side Effect) is caused by Escitalopram (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Diclofenac may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram |
DB11828 | DB12141 | 1,406 | 971 | [
"DDInter1281",
"DDInter817"
] | Neratinib | Gilteritinib | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1406,
24,
971
]
],
[
[
1406,
62,
1135
],
[
1135,
23,
971
]
],
[
[
1406,
63,
72
],
[
72,
24,
971
]
],
[
[
1406,
25,
1339
],
[
1339,
63,
971
]
],
[
[
1406,
64,
529
],
[
529,
24,
971
]
],
[
[
1406,
25,
1017
],
[
1017,
24,
971
]
],
[
[
1406,
24,
829
],
[
829,
63,
971
]
],
[
[
1406,
24,
255
],
[
255,
24,
971
]
],
[
[
1406,
64,
540
],
[
540,
25,
971
]
],
[
[
1406,
25,
68
],
[
68,
64,
971
]
]
] | [
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Neratinib may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Neratinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Gilteritinib |
DB08932 | DB09054 | 1,398 | 384 | [
"DDInter1111",
"DDInter905"
] | Macitentan | Idelalisib | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Major | 2 | [
[
[
1398,
25,
384
]
],
[
[
1398,
63,
305
],
[
305,
24,
384
]
],
[
[
1398,
24,
1619
],
[
1619,
63,
384
]
],
[
[
1398,
25,
760
],
[
760,
63,
384
]
],
[
[
1398,
64,
609
],
[
609,
24,
384
]
],
[
[
1398,
63,
1250
],
[
1250,
25,
384
]
],
[
[
1398,
64,
129
],
[
129,
25,
384
]
],
[
[
1398,
24,
159
],
[
159,
64,
384
]
],
[
[
1398,
25,
913
],
[
913,
64,
384
]
],
[
[
1398,
63,
305
],
[
305,
24,
1627
],
[
1627,
62,
384
]
]
] | [
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
]
] | Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Macitentan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Macitentan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Idelalisib
Macitentan may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Idelalisib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Idelalisib
Macitentan may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Idelalisib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib |
DB00620 | DB11952 | 175 | 800 | [
"DDInter1855",
"DDInter612"
] | Triamcinolone | Duvelisib | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
175,
24,
800
]
],
[
[
175,
63,
663
],
[
663,
24,
800
]
],
[
[
175,
24,
270
],
[
270,
63,
800
]
],
[
[
175,
24,
1683
],
[
1683,
24,
800
]
],
[
[
175,
40,
1486
],
[
1486,
24,
800
]
],
[
[
175,
23,
455
],
[
455,
24,
800
]
],
[
[
175,
1,
617
],
[
617,
24,
800
]
],
[
[
175,
25,
609
],
[
609,
25,
800
]
],
[
[
175,
64,
1057
],
[
1057,
25,
800
]
],
[
[
175,
24,
1478
],
[
1478,
25,
800
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Triamcinolone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Triamcinolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Duvelisib
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Duvelisib |
DB01126 | DB06589 | 1,260 | 1,250 | [
"DDInter611",
"DDInter1400"
] | Dutasteride | Pazopanib | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dut | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1260,
24,
1250
]
],
[
[
1260,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
1260,
21,
28680
],
[
28680,
60,
1250
]
],
[
[
1260,
63,
1419
],
[
1419,
24,
1250
]
],
[
[
1260,
24,
214
],
[
214,
63,
1250
]
],
[
[
1260,
24,
918
],
[
918,
24,
1250
]
],
[
[
1260,
24,
384
],
[
384,
64,
1250
]
],
[
[
1260,
24,
392
],
[
392,
25,
1250
]
],
[
[
1260,
63,
752
],
[
752,
25,
1250
]
],
[
[
1260,
6,
8374
],
[
8374,
52,
2602
],
[
2602,
57,
1250
]
]
] | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Dutasteride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) covaries with {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pazopanib"
]
]
] | Dutasteride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Dutasteride (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Pazopanib (Compound)
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Pazopanib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Pazopanib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Pazopanib
Dutasteride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is downregulated by Pazopanib (Compound) |
DB00477 | DB01344 | 216 | 1,231 | [
"DDInter363",
"DDInter1830"
] | Chlorpromazine | Tolevamer | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV. | Moderate | 1 | [
[
[
216,
24,
1231
]
],
[
[
216,
62,
417
],
[
417,
24,
1231
]
],
[
[
216,
40,
1178
],
[
1178,
24,
1231
]
],
[
[
216,
24,
870
],
[
870,
24,
1231
]
],
[
[
216,
24,
603
],
[
603,
63,
1231
]
],
[
[
216,
1,
508
],
[
508,
24,
1231
]
],
[
[
216,
24,
286
],
[
286,
64,
1231
]
],
[
[
216,
23,
1283
],
[
1283,
64,
1231
]
],
[
[
216,
25,
57
],
[
57,
25,
1231
]
],
[
[
216,
62,
417
],
[
417,
62,
1152
],
[
1152,
24,
1231
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
]
] | Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Chlorpromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Chlorpromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Tolevamer
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may lead to a major life threatening interaction when taken with Tolevamer
Chlorpromazine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Tolevamer
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer |
DB00211 | DB06706 | 1,290 | 468 | [
"DDInter1213",
"DDInter985"
] | Midodrine | Isometheptene | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1290,
24,
468
]
],
[
[
1290,
6,
5214
],
[
5214,
45,
468
]
],
[
[
1290,
24,
480
],
[
480,
24,
468
]
],
[
[
1290,
24,
144
],
[
144,
63,
468
]
],
[
[
1290,
63,
73
],
[
73,
24,
468
]
],
[
[
1290,
24,
1629
],
[
1629,
64,
468
]
],
[
[
1290,
24,
1053
],
[
1053,
25,
468
]
],
[
[
1290,
6,
5214
],
[
5214,
45,
1354
],
[
1354,
24,
468
]
],
[
[
1290,
24,
480
],
[
480,
24,
1354
],
[
1354,
24,
468
]
],
[
[
1290,
24,
688
],
[
688,
63,
480
],
[
480,
24,
468
]
]
] | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Droxidopa"
],
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
],
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
]
] | Midodrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Isometheptene (Compound)
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Isometheptene
Midodrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Droxidopa (Compound) and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene |
DB00054 | DB14276 | 1,432 | 1,631 | [
"DDInter6",
"DDInter1892"
] | Abciximab | Turmeric | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1432,
23,
1631
]
],
[
[
1432,
64,
20
],
[
20,
23,
1631
]
],
[
[
1432,
25,
1018
],
[
1018,
23,
1631
]
],
[
[
1432,
24,
1479
],
[
1479,
23,
1631
]
],
[
[
1432,
63,
942
],
[
942,
23,
1631
]
],
[
[
1432,
64,
20
],
[
20,
24,
1018
],
[
1018,
23,
1631
]
],
[
[
1432,
25,
1018
],
[
1018,
63,
20
],
[
20,
23,
1631
]
],
[
[
1432,
64,
1578
],
[
1578,
25,
20
],
[
20,
23,
1631
]
],
[
[
1432,
25,
500
],
[
500,
64,
20
],
[
20,
23,
1631
]
],
[
[
1432,
24,
1479
],
[
1479,
63,
20
],
[
20,
23,
1631
]
]
] | [
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
]
] | Abciximab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric |
DB00220 | DB11921 | 798 | 1,019 | [
"DDInter1276",
"DDInter492"
] | Nelfinavir | Deflazacort | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Major | 2 | [
[
[
798,
25,
1019
]
],
[
[
798,
24,
959
],
[
959,
24,
1019
]
],
[
[
798,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
798,
25,
629
],
[
629,
24,
1019
]
],
[
[
798,
63,
176
],
[
176,
24,
1019
]
],
[
[
798,
25,
214
],
[
214,
63,
1019
]
],
[
[
798,
24,
723
],
[
723,
25,
1019
]
],
[
[
798,
1,
215
],
[
215,
25,
1019
]
],
[
[
798,
25,
283
],
[
283,
64,
1019
]
],
[
[
798,
40,
1327
],
[
1327,
25,
1019
]
]
] | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Indinavir"
],
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
]
] | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nelfinavir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nelfinavir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Deflazacort
Nelfinavir (Compound) resembles Indinavir (Compound) and Indinavir may lead to a major life threatening interaction when taken with Deflazacort
Nelfinavir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Deflazacort
Nelfinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Deflazacort |
DB00524 | DB01261 | 811 | 170 | [
"DDInter1199",
"DDInter1679"
] | Metolazone | Sitagliptin | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
811,
24,
170
]
],
[
[
811,
18,
1866
],
[
1866,
57,
170
]
],
[
[
811,
21,
28850
],
[
28850,
60,
170
]
],
[
[
811,
24,
52
],
[
52,
62,
170
]
],
[
[
811,
24,
708
],
[
708,
63,
170
]
],
[
[
811,
63,
1179
],
[
1179,
24,
170
]
],
[
[
811,
24,
1674
],
[
1674,
24,
170
]
],
[
[
811,
1,
1605
],
[
1605,
24,
170
]
],
[
[
811,
40,
1014
],
[
1014,
24,
170
]
],
[
[
811,
18,
1866
],
[
1866,
56,
4973
],
[
4973,
45,
170
]
]
] | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} (Compound) downregulates {v} (Gene)",
"SLC38A1"
],
[
"SLC38A1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
],
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Metolazone",
"{u} (Compound) downregulates {v} (Gene)",
"SLC38A1"
],
[
"SLC38A1",
"{u} (Gene) is regulated by {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagliptin"
]
]
] | Metolazone (Compound) downregulates SLC38A1 (Gene) and SLC38A1 (Gene) is downregulated by Sitagliptin (Compound)
Metolazone (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Metolazone (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Metolazone (Compound) downregulates SLC38A1 (Gene) and SLC38A1 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Sitagliptin (Compound) |
DB00880 | DB11921 | 359 | 1,019 | [
"DDInter360",
"DDInter492"
] | Chlorothiazide | Deflazacort | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
359,
24,
1019
]
],
[
[
359,
24,
959
],
[
959,
24,
1019
]
],
[
[
359,
40,
1326
],
[
1326,
24,
1019
]
],
[
[
359,
63,
355
],
[
355,
24,
1019
]
],
[
[
359,
24,
1385
],
[
1385,
63,
1019
]
],
[
[
359,
62,
126
],
[
126,
24,
1019
]
],
[
[
359,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
359,
24,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
359,
40,
1326
],
[
1326,
63,
959
],
[
959,
24,
1019
]
],
[
[
359,
63,
355
],
[
355,
63,
443
],
[
443,
24,
1019
]
]
] | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
]
] | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Chlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort |
DB00845 | DB06616 | 1,490 | 594 | [
"DDInter406",
"DDInter224"
] | Clofazimine | Bosutinib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid]. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
1490,
24,
594
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1490,
21,
28709
],
[
28709,
60,
594
]
],
[
[
1490,
23,
112
],
[
112,
23,
594
]
],
[
[
1490,
24,
1559
],
[
1559,
24,
594
]
],
[
[
1490,
24,
774
],
[
774,
63,
594
]
],
[
[
1490,
63,
485
],
[
485,
24,
594
]
],
[
[
1490,
25,
478
],
[
478,
24,
594
]
],
[
[
1490,
25,
985
],
[
985,
64,
594
]
],
[
[
1490,
25,
1493
],
[
1493,
25,
594
]
]
] | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
]
] | Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Clofazimine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Clofazimine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Clofazimine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Bosutinib
Clofazimine may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Bosutinib |
DB00427 | DB00985 | 1,233 | 1,443 | [
"DDInter1879",
"DDInter562"
] | Triprolidine | Dimenhydrinate | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.[L32980,L32985,L32995] Dimenhydrinate is a combination of [Diphenhydramine] and [8-chlorotheophylline] in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline. The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation. Dimenhydrinate was granted FDA approval on 31 May 1972. | Moderate | 1 | [
[
[
1233,
24,
1443
]
],
[
[
1233,
1,
11268
],
[
11268,
1,
1443
]
],
[
[
1233,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
1233,
63,
357
],
[
357,
1,
1443
]
],
[
[
1233,
24,
358
],
[
358,
1,
1443
]
],
[
[
1233,
10,
11679
],
[
11679,
44,
1443
]
],
[
[
1233,
6,
10104
],
[
10104,
45,
1443
]
],
[
[
1233,
24,
662
],
[
662,
24,
1443
]
],
[
[
1233,
63,
1242
],
[
1242,
24,
1443
]
],
[
[
1233,
25,
1621
],
[
1621,
25,
1443
]
]
] | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u} (Compound) resembles {v} (Compound)",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} (Compound) palliates {v} (Disease)",
"atopic dermatitis"
],
[
"atopic dermatitis",
"{u} (Disease) is treated by {v} (Compound)",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Triprolidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimenhydrinate"
]
]
] | Triprolidine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Dimenhydrinate (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine (Compound) resembles Dimenhydrinate (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Dimenhydrinate (Compound)
Triprolidine (Compound) palliates atopic dermatitis (Disease) and atopic dermatitis (Disease) is treated by Dimenhydrinate (Compound)
Triprolidine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Dimenhydrinate (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Triprolidine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Dimenhydrinate |
DB00334 | DB09268 | 867 | 1,662 | [
"DDInter1326",
"DDInter1464"
] | Olanzapine | Picosulfuric acid | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
867,
24,
1662
]
],
[
[
867,
24,
484
],
[
484,
63,
1662
]
],
[
[
867,
24,
1618
],
[
1618,
24,
1662
]
],
[
[
867,
1,
87
],
[
87,
24,
1662
]
],
[
[
867,
64,
475
],
[
475,
24,
1662
]
],
[
[
867,
23,
112
],
[
112,
24,
1662
]
],
[
[
867,
63,
702
],
[
702,
24,
1662
]
],
[
[
867,
25,
1311
],
[
1311,
24,
1662
]
],
[
[
867,
40,
1408
],
[
1408,
24,
1662
]
],
[
[
867,
1,
695
],
[
695,
25,
1662
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Loxapine"
],
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
]
] | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Olanzapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Picosulfuric acid |
DB09075 | DB11095 | 498 | 235 | [
"DDInter621",
"DDInter505"
] | Edoxaban | Desirudin | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. | Major | 2 | [
[
[
498,
25,
235
]
],
[
[
498,
23,
297
],
[
297,
23,
235
]
],
[
[
498,
63,
1100
],
[
1100,
24,
235
]
],
[
[
498,
24,
1004
],
[
1004,
24,
235
]
],
[
[
498,
24,
321
],
[
321,
63,
235
]
],
[
[
498,
64,
578
],
[
578,
24,
235
]
],
[
[
498,
64,
1409
],
[
1409,
25,
235
]
],
[
[
498,
25,
1421
],
[
1421,
64,
235
]
],
[
[
498,
23,
297
],
[
297,
62,
578
],
[
578,
24,
235
]
],
[
[
498,
63,
1100
],
[
1100,
1,
643
],
[
643,
24,
235
]
]
] | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
],
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
]
] | Edoxaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Desirudin
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Edoxaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Edoxaban may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Desirudin
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Desirudin
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound) and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin |
DB00398 | DB12010 | 79 | 214 | [
"DDInter1702",
"DDInter785"
] | Sorafenib | Fostamatinib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
79,
24,
214
]
],
[
[
79,
24,
690
],
[
690,
24,
214
]
],
[
[
79,
24,
861
],
[
861,
63,
214
]
],
[
[
79,
25,
924
],
[
924,
24,
214
]
],
[
[
79,
63,
600
],
[
600,
24,
214
]
],
[
[
79,
64,
576
],
[
576,
24,
214
]
],
[
[
79,
1,
292
],
[
292,
24,
214
]
],
[
[
79,
25,
1375
],
[
1375,
63,
214
]
],
[
[
79,
23,
1135
],
[
1135,
24,
214
]
],
[
[
79,
24,
609
],
[
609,
25,
214
]
]
] | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} (Compound) resembles {v} (Compound)",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib (Compound) resembles Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib |
DB00668 | DB01309 | 874 | 1,254 | [
"DDInter652",
"DDInter933"
] | Epinephrine | Insulin glulisine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades,,. On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
874,
24,
1254
]
],
[
[
874,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
874,
25,
887
],
[
887,
24,
1254
]
],
[
[
874,
24,
480
],
[
480,
24,
1254
]
],
[
[
874,
24,
1529
],
[
1529,
63,
1254
]
],
[
[
874,
23,
1399
],
[
1399,
63,
1254
]
],
[
[
874,
40,
1636
],
[
1636,
24,
1254
]
],
[
[
874,
64,
1523
],
[
1523,
24,
1254
]
],
[
[
874,
25,
729
],
[
729,
63,
1254
]
],
[
[
874,
63,
1645
],
[
1645,
62,
333
],
[
333,
23,
1254
]
]
] | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin glulisine"
]
]
] | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may lead to a major life threatening interaction when taken with Pindolol and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may lead to a major life threatening interaction when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may lead to a major life threatening interaction when taken with Penbutolol and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine |
DB06372 | DB11988 | 259 | 270 | [
"DDInter1594",
"DDInter1321"
] | Rilonacept | Ocrelizumab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
259,
24,
270
]
],
[
[
259,
23,
1193
],
[
1193,
23,
270
]
],
[
[
259,
62,
1461
],
[
1461,
23,
270
]
],
[
[
259,
24,
1060
],
[
1060,
63,
270
]
],
[
[
259,
63,
134
],
[
134,
24,
270
]
],
[
[
259,
24,
1500
],
[
1500,
24,
270
]
],
[
[
259,
64,
980
],
[
980,
24,
270
]
],
[
[
259,
25,
725
],
[
725,
63,
270
]
],
[
[
259,
25,
1583
],
[
1583,
24,
270
]
],
[
[
259,
25,
962
],
[
962,
25,
270
]
]
] | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
],
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
]
] | Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab and Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Rilonacept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab |
DB00275 | DB09038 | 217 | 1,450 | [
"DDInter1330",
"DDInter636"
] | Olmesartan | Empagliflozin | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
217,
24,
1450
]
],
[
[
217,
24,
1061
],
[
1061,
24,
1450
]
],
[
[
217,
1,
911
],
[
911,
24,
1450
]
],
[
[
217,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
217,
24,
913
],
[
913,
63,
1450
]
],
[
[
217,
24,
1061
],
[
1061,
63,
461
],
[
461,
24,
1450
]
],
[
[
217,
1,
911
],
[
911,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
217,
63,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
1450
]
],
[
[
217,
24,
870
],
[
870,
1,
1103
],
[
1103,
23,
1450
]
],
[
[
217,
24,
1510
],
[
1510,
64,
1551
],
[
1551,
24,
1450
]
]
] | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
]
] | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin |
DB08868 | DB15091 | 1,011 | 676 | [
"DDInter737",
"DDInter1901"
] | Fingolimod | Upadacitinib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1011,
25,
676
]
],
[
[
1011,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1011,
24,
748
],
[
748,
24,
676
]
],
[
[
1011,
64,
1593
],
[
1593,
24,
676
]
],
[
[
1011,
25,
1375
],
[
1375,
24,
676
]
],
[
[
1011,
64,
1184
],
[
1184,
25,
676
]
],
[
[
1011,
25,
503
],
[
503,
25,
676
]
],
[
[
1011,
25,
899
],
[
899,
64,
676
]
],
[
[
1011,
63,
915
],
[
915,
25,
676
]
],
[
[
1011,
63,
1430
],
[
1430,
63,
1184
],
[
1184,
25,
676
]
]
] | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisocabtagene maraleucel"
],
[
"Lisocabtagene maraleucel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
]
] | Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fingolimod may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fingolimod may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fingolimod may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Fingolimod may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Upadacitinib
Fingolimod may lead to a major life threatening interaction when taken with Lisocabtagene maraleucel and Lisocabtagene maraleucel may lead to a major life threatening interaction when taken with Upadacitinib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Upadacitinib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib |
DB01246 | DB08871 | 820 | 36 | [
"DDInter45",
"DDInter666"
] | Alimemazine | Eribulin | A phenothiazine derivative that is used as an antipruritic. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Moderate | 1 | [
[
[
820,
24,
36
]
],
[
[
820,
63,
122
],
[
122,
23,
36
]
],
[
[
820,
62,
1247
],
[
1247,
23,
36
]
],
[
[
820,
24,
519
],
[
519,
24,
36
]
],
[
[
820,
63,
1424
],
[
1424,
24,
36
]
],
[
[
820,
24,
180
],
[
180,
63,
36
]
],
[
[
820,
74,
216
],
[
216,
24,
36
]
],
[
[
820,
40,
9
],
[
9,
24,
36
]
],
[
[
820,
25,
351
],
[
351,
63,
36
]
],
[
[
820,
64,
675
],
[
675,
24,
36
]
]
] | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
]
] | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Eribulin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine (Compound) resembles Chlorpromazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alimemazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Eribulin |
DB00888 | DB11601 | 1,001 | 1,270 | [
"DDInter1133",
"DDInter1889"
] | Mechlorethamine | Tuberculin purified protein derivative | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1001,
24,
1270
]
],
[
[
1001,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1001,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1001,
63,
1555
],
[
1555,
24,
1270
]
],
[
[
1001,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
1001,
25,
976
],
[
976,
24,
1270
]
],
[
[
1001,
24,
738
],
[
738,
63,
1270
]
],
[
[
1001,
40,
450
],
[
450,
24,
1270
]
],
[
[
1001,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
1001,
64,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mechlorethamine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00514 | DB01501 | 506 | 1,118 | [
"DDInter527",
"DDInter549"
] | Dextromethorphan | Difenoxin | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. | Moderate | 1 | [
[
[
506,
24,
1118
]
],
[
[
506,
63,
576
],
[
576,
1,
1118
]
],
[
[
506,
24,
1688
],
[
1688,
40,
1118
]
],
[
[
506,
63,
194
],
[
194,
40,
1118
]
],
[
[
506,
6,
6591
],
[
6591,
45,
1118
]
],
[
[
506,
63,
78
],
[
78,
24,
1118
]
],
[
[
506,
24,
843
],
[
843,
63,
1118
]
],
[
[
506,
24,
1335
],
[
1335,
24,
1118
]
],
[
[
506,
25,
1301
],
[
1301,
24,
1118
]
],
[
[
506,
64,
1230
],
[
1230,
24,
1118
]
]
] | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"OPRM1"
],
[
"OPRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
]
] | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Difenoxin (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Difenoxin (Compound)
Dextromethorphan (Compound) binds OPRM1 (Gene) and OPRM1 (Gene) is bound by Difenoxin (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Dextromethorphan may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin
Dextromethorphan may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin |
DB01192 | DB04837 | 560 | 649 | [
"DDInter1372",
"DDInter407"
] | Oxymorphone | Clofedanol | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
560,
24,
649
]
],
[
[
560,
63,
1376
],
[
1376,
24,
649
]
],
[
[
560,
63,
832
],
[
832,
40,
649
]
],
[
[
560,
24,
1511
],
[
1511,
40,
649
]
],
[
[
560,
24,
1311
],
[
1311,
24,
649
]
],
[
[
560,
24,
1609
],
[
1609,
63,
649
]
],
[
[
560,
40,
828
],
[
828,
24,
649
]
],
[
[
560,
75,
475
],
[
475,
24,
649
]
],
[
[
560,
63,
662
],
[
662,
35,
649
]
],
[
[
560,
63,
1376
],
[
1376,
74,
21
],
[
21,
24,
649
]
]
] | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
]
] | Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Clofedanol (Compound)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) resembles Clofedanol (Compound)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone (Compound) resembles Morphine (Compound) and Oxymorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Amitriptyline (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol |
DB11095 | DB15233 | 235 | 1,650 | [
"DDInter505",
"DDInter142"
] | Desirudin | Avapritinib | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
235,
25,
1650
]
],
[
[
235,
63,
557
],
[
557,
24,
1650
]
],
[
[
235,
24,
738
],
[
738,
24,
1650
]
],
[
[
235,
64,
1512
],
[
1512,
25,
1650
]
],
[
[
235,
63,
578
],
[
578,
25,
1650
]
],
[
[
235,
25,
1421
],
[
1421,
25,
1650
]
],
[
[
235,
64,
1274
],
[
1274,
37,
1650
]
],
[
[
235,
63,
557
],
[
557,
63,
1578
],
[
1578,
25,
1650
]
],
[
[
235,
63,
1039
],
[
1039,
24,
1374
],
[
1374,
24,
1650
]
],
[
[
235,
24,
738
],
[
738,
63,
1101
],
[
1101,
24,
1650
]
]
] | [
[
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
]
] | Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Desirudin may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Avapritinib
Desirudin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Avapritinib
Desirudin may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Avapritinib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib |
DB00009 | DB01381 | 1,271 | 958 | [
"DDInter56",
"DDInter819"
] | Alteplase | Ginkgo biloba | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964. EGb761 contains 6% terpene lactones and 24% flavonoid glycosides. Flavonoids include quercetin, rutin, kaempferol, and isorhamnetin. Lactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and ginkgotoxin, a lactone that is structurally related to [pyridoxine]. _Ginkgo biloba_ is an herbal plant that is now cultivated worldwide. It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. After its nootropic properties were discovered, _ginkgo biloba_ has gained attention as a therapeutic ingredient for memory and concentration enhancement in cognitive impairment and neurogenerative diseases, such as dementia. _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders, and glaucoma. _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA, and Health Canada. _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization. | Moderate | 1 | [
[
[
1271,
24,
958
]
],
[
[
1271,
24,
1347
],
[
1347,
24,
958
]
],
[
[
1271,
25,
126
],
[
126,
24,
958
]
],
[
[
1271,
25,
792
],
[
792,
63,
958
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
958
]
],
[
[
1271,
24,
578
],
[
578,
63,
958
]
],
[
[
1271,
24,
1347
],
[
1347,
64,
126
],
[
126,
24,
958
]
],
[
[
1271,
25,
126
],
[
126,
25,
1347
],
[
1347,
24,
958
]
],
[
[
1271,
24,
1317
],
[
1317,
63,
126
],
[
126,
24,
958
]
],
[
[
1271,
24,
121
],
[
121,
24,
1347
],
[
1347,
24,
958
]
]
] | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
]
] | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba |
DB01177 | DB11642 | 77 | 938 | [
"DDInter904",
"DDInter1480"
] | Idarubicin | Pitolisant | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
77,
24,
938
]
],
[
[
77,
62,
112
],
[
112,
23,
938
]
],
[
[
77,
63,
600
],
[
600,
24,
938
]
],
[
[
77,
24,
1228
],
[
1228,
24,
938
]
],
[
[
77,
24,
927
],
[
927,
63,
938
]
],
[
[
77,
74,
322
],
[
322,
24,
938
]
],
[
[
77,
25,
676
],
[
676,
63,
938
]
],
[
[
77,
64,
770
],
[
770,
24,
938
]
],
[
[
77,
25,
1154
],
[
1154,
25,
938
]
],
[
[
77,
25,
351
],
[
351,
64,
938
]
]
] | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
]
] | Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin (Compound) resembles Epirubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Idarubicin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Pitolisant
Idarubicin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Pitolisant |
DB01205 | DB01589 | 1,404 | 481 | [
"DDInter748",
"DDInter1552"
] | Flumazenil | Quazepam | Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other receptors. | Moderate | 1 | [
[
[
1404,
24,
481
]
],
[
[
1404,
63,
1216
],
[
1216,
1,
481
]
],
[
[
1404,
24,
1418
],
[
1418,
1,
481
]
],
[
[
1404,
63,
905
],
[
905,
40,
481
]
],
[
[
1404,
6,
5812
],
[
5812,
45,
481
]
],
[
[
1404,
21,
28705
],
[
28705,
60,
481
]
],
[
[
1404,
64,
1264
],
[
1264,
24,
481
]
],
[
[
1404,
63,
1216
],
[
1216,
1,
406
],
[
406,
1,
481
]
],
[
[
1404,
24,
1418
],
[
1418,
1,
406
],
[
406,
1,
481
]
],
[
[
1404,
63,
905
],
[
905,
40,
406
],
[
406,
1,
481
]
]
] | [
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} (Compound) binds {v} (Gene)",
"GABRA3"
],
[
"GABRA3",
"{u} (Gene) is bound by {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} (Compound) causes {v} (Side Effect)",
"Drowsiness"
],
[
"Drowsiness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
],
[
"Diazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
],
[
"Diazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Flumazenil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
],
[
"Diazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
]
] | Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Quazepam (Compound)
Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Flumazenil (Compound) binds GABRA3 (Gene) and GABRA3 (Gene) is bound by Quazepam (Compound)
Flumazenil (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Quazepam (Compound)
Flumazenil may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Quazepam (Compound)
Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Quazepam (Compound)
Flumazenil may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Quazepam (Compound) |
DB00443 | DB00580 | 251 | 311 | [
"DDInter195",
"DDInter1910"
] | Betamethasone | Valdecoxib | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
251,
24,
311
]
],
[
[
251,
24,
473
],
[
473,
63,
311
]
],
[
[
251,
24,
663
],
[
663,
24,
311
]
],
[
[
251,
63,
1560
],
[
1560,
24,
311
]
],
[
[
251,
62,
1018
],
[
1018,
24,
311
]
],
[
[
251,
64,
1314
],
[
1314,
24,
311
]
],
[
[
251,
1,
1220
],
[
1220,
63,
311
]
],
[
[
251,
40,
167
],
[
167,
63,
311
]
],
[
[
251,
25,
497
],
[
497,
64,
311
]
],
[
[
251,
24,
629
],
[
629,
64,
311
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valdecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valdecoxib"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone may lead to a major life threatening interaction when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Betamethasone may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Valdecoxib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Valdecoxib |
DB00215 | DB00358 | 1,230 | 1,010 | [
"DDInter388",
"DDInter1140"
] | Citalopram | Mefloquine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953] | Major | 2 | [
[
[
1230,
25,
1010
]
],
[
[
1230,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
1230,
18,
7623
],
[
7623,
57,
1010
]
],
[
[
1230,
21,
29362
],
[
29362,
60,
1010
]
],
[
[
1230,
24,
1311
],
[
1311,
62,
1010
]
],
[
[
1230,
23,
112
],
[
112,
62,
1010
]
],
[
[
1230,
25,
823
],
[
823,
63,
1010
]
],
[
[
1230,
64,
521
],
[
521,
24,
1010
]
],
[
[
1230,
24,
477
],
[
477,
63,
1010
]
],
[
[
1230,
25,
1181
],
[
1181,
24,
1010
]
]
] | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} (Compound) downregulates {v} (Gene)",
"RRP12"
],
[
"RRP12",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Leukocytosis"
],
[
"Leukocytosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
]
] | Citalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Citalopram (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Mefloquine (Compound)
Citalopram (Compound) causes Leukocytosis (Side Effect) and Leukocytosis (Side Effect) is caused by Mefloquine (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Citalopram may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Citalopram may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Citalopram may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine |
DB00601 | DB01156 | 453 | 593 | [
"DDInter1073",
"DDInter252"
] | Linezolid | Bupropion | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. | Major | 2 | [
[
[
453,
25,
593
]
],
[
[
453,
21,
28757
],
[
28757,
60,
593
]
],
[
[
453,
63,
1214
],
[
1214,
24,
593
]
],
[
[
453,
24,
126
],
[
126,
24,
593
]
],
[
[
453,
24,
1637
],
[
1637,
63,
593
]
],
[
[
453,
64,
506
],
[
506,
24,
593
]
],
[
[
453,
25,
1510
],
[
1510,
64,
593
]
],
[
[
453,
24,
104
],
[
104,
25,
593
]
],
[
[
453,
64,
1048
],
[
1048,
25,
593
]
],
[
[
453,
25,
1377
],
[
1377,
25,
593
]
]
] | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxapram"
],
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
]
] | Linezolid (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Linezolid may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Linezolid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Bupropion
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may lead to a major life threatening interaction when taken with Bupropion
Linezolid may lead to a major life threatening interaction when taken with Doxapram and Doxapram may lead to a major life threatening interaction when taken with Bupropion
Linezolid may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bupropion |
DB00366 | DB00690 | 1,594 | 1,216 | [
"DDInter600",
"DDInter762"
] | Doxylamine | Flurazepam | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
1594,
24,
1216
]
],
[
[
1594,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
1594,
24,
481
],
[
481,
40,
1216
]
],
[
[
1594,
63,
902
],
[
902,
40,
1216
]
],
[
[
1594,
63,
1174
],
[
1174,
1,
1216
]
],
[
[
1594,
21,
28905
],
[
28905,
60,
1216
]
],
[
[
1594,
24,
832
],
[
832,
63,
1216
]
],
[
[
1594,
24,
1233
],
[
1233,
24,
1216
]
],
[
[
1594,
63,
1648
],
[
1648,
24,
1216
]
],
[
[
1594,
35,
272
],
[
272,
63,
1216
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Flurazepam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Flurazepam (Compound)
Doxylamine (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Flurazepam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam |
DB00705 | DB01611 | 441 | 1,487 | [
"DDInter496",
"DDInter893"
] | Delavirdine | Hydroxychloroquine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. | Moderate | 1 | [
[
[
441,
24,
1487
]
],
[
[
441,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
441,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
441,
63,
723
],
[
723,
24,
1487
]
],
[
[
441,
24,
1283
],
[
1283,
24,
1487
]
],
[
[
441,
24,
286
],
[
286,
63,
1487
]
],
[
[
441,
25,
1468
],
[
1468,
63,
1487
]
],
[
[
441,
64,
147
],
[
147,
24,
1487
]
],
[
[
441,
62,
63
],
[
63,
24,
1487
]
],
[
[
441,
25,
973
],
[
973,
24,
1487
]
]
] | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
]
] | Delavirdine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Delavirdine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Delavirdine may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine |
DB00880 | DB11348 | 359 | 1,065 | [
"DDInter360",
"DDInter279"
] | Chlorothiazide | Calcium Phosphate | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
359,
24,
1065
]
],
[
[
359,
40,
1014
],
[
1014,
24,
1065
]
],
[
[
359,
62,
1620
],
[
1620,
24,
1065
]
],
[
[
359,
23,
1669
],
[
1669,
24,
1065
]
],
[
[
359,
40,
1014
],
[
1014,
23,
1620
],
[
1620,
24,
1065
]
],
[
[
359,
62,
1620
],
[
1620,
62,
1014
],
[
1014,
24,
1065
]
],
[
[
359,
62,
964
],
[
964,
23,
1014
],
[
1014,
24,
1065
]
],
[
[
359,
40,
811
],
[
811,
40,
1014
],
[
1014,
24,
1065
]
],
[
[
359,
40,
1577
],
[
1577,
62,
1620
],
[
1620,
24,
1065
]
],
[
[
359,
40,
178
],
[
178,
1,
1014
],
[
1014,
24,
1065
]
]
] | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
]
] | Chlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide (Compound) resembles Metolazone (Compound) and Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Chlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate |
DB00046 | DB11255 | 1,179 | 1,371 | [
"DDInter940",
"DDInter374"
] | Insulin lispro | Chromium picolinate | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor . | Moderate | 1 | [
[
[
1179,
24,
1371
]
],
[
[
1179,
24,
245
],
[
245,
24,
1371
]
],
[
[
1179,
24,
1385
],
[
1385,
63,
1371
]
],
[
[
1179,
24,
245
],
[
245,
24,
5
],
[
5,
24,
1371
]
],
[
[
1179,
24,
5
],
[
5,
63,
245
],
[
245,
24,
1371
]
],
[
[
1179,
24,
959
],
[
959,
1,
245
],
[
245,
24,
1371
]
],
[
[
1179,
23,
721
],
[
721,
62,
245
],
[
245,
24,
1371
]
],
[
[
1179,
23,
333
],
[
333,
23,
245
],
[
245,
24,
1371
]
],
[
[
1179,
24,
245
],
[
245,
40,
959
],
[
959,
24,
1371
]
],
[
[
1179,
24,
52
],
[
52,
62,
170
],
[
170,
24,
1371
]
]
] | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
],
[
"Methylcellulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
]
] | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methylcellulose may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate |
DB06210 | DB09330 | 72 | 985 | [
"DDInter631",
"DDInter1352"
] | Eltrombopag | Osimertinib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Moderate | 1 | [
[
[
72,
24,
985
]
],
[
[
72,
24,
119
],
[
119,
63,
985
]
],
[
[
72,
63,
663
],
[
663,
24,
985
]
],
[
[
72,
24,
286
],
[
286,
24,
985
]
],
[
[
72,
25,
990
],
[
990,
24,
985
]
],
[
[
72,
24,
484
],
[
484,
64,
985
]
],
[
[
72,
25,
1510
],
[
1510,
25,
985
]
],
[
[
72,
63,
322
],
[
322,
25,
985
]
],
[
[
72,
24,
996
],
[
996,
25,
985
]
],
[
[
72,
25,
1339
],
[
1339,
64,
985
]
]
] | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Eltrombopag may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Eltrombopag may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Osimertinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Osimertinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Osimertinib
Eltrombopag may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may lead to a major life threatening interaction when taken with Osimertinib |
DB06273 | DB09121 | 980 | 1,328 | [
"DDInter1824",
"DDInter140"
] | Tocilizumab | Aurothioglucose | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective. | Moderate | 1 | [
[
[
980,
24,
1328
]
],
[
[
980,
63,
367
],
[
367,
24,
1328
]
],
[
[
980,
64,
581
],
[
581,
24,
1328
]
],
[
[
980,
24,
310
],
[
310,
24,
1328
]
],
[
[
980,
25,
375
],
[
375,
24,
1328
]
],
[
[
980,
24,
270
],
[
270,
63,
1328
]
],
[
[
980,
63,
1487
],
[
1487,
25,
1328
]
],
[
[
980,
64,
1377
],
[
1377,
25,
1328
]
],
[
[
980,
25,
1292
],
[
1292,
25,
1328
]
],
[
[
980,
63,
367
],
[
367,
63,
581
],
[
581,
24,
1328
]
]
] | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
]
] | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Tocilizumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Tocilizumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Aurothioglucose
Tocilizumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Aurothioglucose
Tocilizumab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Aurothioglucose
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose |
DB00852 | DB01367 | 1,445 | 1,163 | [
"DDInter1545",
"DDInter1572"
] | Pseudoephedrine | Rasagiline | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
1445,
24,
1163
]
],
[
[
1445,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
1445,
63,
590
],
[
590,
24,
1163
]
],
[
[
1445,
74,
1466
],
[
1466,
24,
1163
]
],
[
[
1445,
24,
473
],
[
473,
24,
1163
]
],
[
[
1445,
1,
22
],
[
22,
24,
1163
]
],
[
[
1445,
24,
1296
],
[
1296,
63,
1163
]
],
[
[
1445,
25,
1629
],
[
1629,
64,
1163
]
],
[
[
1445,
25,
1053
],
[
1053,
25,
1163
]
],
[
[
1445,
37,
247
],
[
247,
64,
1163
]
]
] | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound)",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rasagiline"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rasagiline"
]
]
] | Pseudoephedrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Pseudoephedrine (Compound) resembles Phenylpropanolamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Pseudoephedrine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Rasagiline
Pseudoephedrine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Rasagiline
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Pseudoephedrine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Rasagiline |
DB00741 | DB09020 | 167 | 28 | [
"DDInter885",
"DDInter212"
] | Hydrocortisone | Bisacodyl | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
167,
24,
28
]
],
[
[
167,
18,
20113
],
[
20113,
46,
28
]
],
[
[
167,
7,
3361
],
[
3361,
46,
28
]
],
[
[
167,
6,
1899
],
[
1899,
46,
28
]
],
[
[
167,
7,
7669
],
[
7669,
57,
28
]
],
[
[
167,
21,
28666
],
[
28666,
60,
28
]
],
[
[
167,
25,
739
],
[
739,
24,
28
]
],
[
[
167,
24,
938
],
[
938,
63,
28
]
],
[
[
167,
40,
870
],
[
870,
24,
28
]
],
[
[
167,
24,
954
],
[
954,
24,
28
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) upregulates {v} (Gene)",
"NFIL3"
],
[
"NFIL3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
]
] | Hydrocortisone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Bisacodyl (Compound)
Hydrocortisone (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Bisacodyl (Compound)
Hydrocortisone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Bisacodyl (Compound)
Hydrocortisone (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Bisacodyl (Compound)
Hydrocortisone (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl |
DB00656 | DB06699 | 827 | 774 | [
"DDInter1851",
"DDInter493"
] | Trazodone | Degarelix | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
827,
24,
774
]
],
[
[
827,
63,
521
],
[
521,
1,
774
]
],
[
[
827,
21,
29232
],
[
29232,
60,
774
]
],
[
[
827,
23,
112
],
[
112,
23,
774
]
],
[
[
827,
24,
888
],
[
888,
24,
774
]
],
[
[
827,
24,
484
],
[
484,
63,
774
]
],
[
[
827,
63,
355
],
[
355,
24,
774
]
],
[
[
827,
40,
1630
],
[
1630,
24,
774
]
],
[
[
827,
25,
1133
],
[
1133,
24,
774
]
],
[
[
827,
1,
623
],
[
623,
24,
774
]
]
] | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
]
] | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Trazodone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Trazodone (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Trazodone may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Trazodone (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix |
DB00390 | DB05351 | 1,252 | 101 | [
"DDInter554",
"DDInter519"
] | Digoxin | Dexlansoprazole | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme. | Moderate | 1 | [
[
[
1252,
24,
101
]
],
[
[
1252,
24,
1479
],
[
1479,
23,
101
]
],
[
[
1252,
24,
1468
],
[
1468,
62,
101
]
],
[
[
1252,
23,
361
],
[
361,
24,
101
]
],
[
[
1252,
25,
609
],
[
609,
24,
101
]
],
[
[
1252,
24,
1231
],
[
1231,
24,
101
]
],
[
[
1252,
63,
1152
],
[
1152,
24,
101
]
],
[
[
1252,
24,
1604
],
[
1604,
63,
101
]
],
[
[
1252,
24,
663
],
[
663,
25,
101
]
],
[
[
1252,
24,
1406
],
[
1406,
64,
101
]
]
] | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexlansoprazole"
]
]
] | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Digoxin may cause a minor interaction that can limit clinical effects when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Digoxin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Dexlansoprazole
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Dexlansoprazole |
DB09039 | DB11652 | 1,670 | 1,155 | [
"DDInter629",
"DDInter1891"
] | Eliglustat | Tucatinib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers ( | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Major | 2 | [
[
[
1670,
25,
1155
]
],
[
[
1670,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1670,
64,
609
],
[
609,
24,
1155
]
],
[
[
1670,
63,
522
],
[
522,
24,
1155
]
],
[
[
1670,
24,
1320
],
[
1320,
63,
1155
]
],
[
[
1670,
24,
1094
],
[
1094,
24,
1155
]
],
[
[
1670,
25,
384
],
[
384,
24,
1155
]
],
[
[
1670,
25,
351
],
[
351,
64,
1155
]
],
[
[
1670,
63,
134
],
[
134,
25,
1155
]
],
[
[
1670,
24,
927
],
[
927,
64,
1155
]
]
] | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
]
] | Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Eliglustat may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Eliglustat may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Eliglustat may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Tucatinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Tucatinib |
DB01211 | DB01607 | 609 | 1,390 | [
"DDInter393",
"DDInter1803"
] | Clarithromycin | Ticarcillin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | An antibiotic derived from penicillin similar to carbenicillin in action. | Minor | 0 | [
[
[
609,
23,
1390
]
],
[
[
609,
62,
514
],
[
514,
40,
1390
]
],
[
[
609,
23,
339
],
[
339,
1,
1390
]
],
[
[
609,
62,
950
],
[
950,
1,
1390
]
],
[
[
609,
18,
3023
],
[
3023,
57,
1390
]
],
[
[
609,
21,
28680
],
[
28680,
60,
1390
]
],
[
[
609,
64,
126
],
[
126,
24,
1390
]
],
[
[
609,
63,
1096
],
[
1096,
24,
1390
]
],
[
[
609,
24,
1662
],
[
1662,
63,
1390
]
],
[
[
609,
63,
663
],
[
663,
25,
1390
]
]
] | [
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzylpenicillin"
],
[
"Benzylpenicillin",
"{u} (Compound) resembles {v} (Compound)",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} (Compound) resembles {v} (Compound)",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cloxacillin"
],
[
"Cloxacillin",
"{u} (Compound) resembles {v} (Compound)",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) downregulates {v} (Gene)",
"RUVBL1"
],
[
"RUVBL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticarcillin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticarcillin"
]
]
] | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Benzylpenicillin and Benzylpenicillin (Compound) resembles Ticarcillin (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Bacampicillin and Bacampicillin (Compound) resembles Ticarcillin (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cloxacillin and Cloxacillin (Compound) resembles Ticarcillin (Compound)
Clarithromycin (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Ticarcillin (Compound)
Clarithromycin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Ticarcillin (Compound)
Clarithromycin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ticarcillin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ticarcillin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Ticarcillin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Ticarcillin |
DB00586 | DB01110 | 1,512 | 86 | [
"DDInter537",
"DDInter1209"
] | Diclofenac | Miconazole | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to miconazole among susceptible organisms is relatively low. | Moderate | 1 | [
[
[
1512,
24,
86
]
],
[
[
1512,
6,
6365
],
[
6365,
45,
86
]
],
[
[
1512,
21,
29122
],
[
29122,
60,
86
]
],
[
[
1512,
24,
318
],
[
318,
62,
86
]
],
[
[
1512,
23,
307
],
[
307,
23,
86
]
],
[
[
1512,
24,
222
],
[
222,
23,
86
]
],
[
[
1512,
63,
1230
],
[
1230,
23,
86
]
],
[
[
1512,
24,
976
],
[
976,
63,
86
]
],
[
[
1512,
25,
1409
],
[
1409,
63,
86
]
],
[
[
1512,
63,
376
],
[
376,
24,
86
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
]
] | Diclofenac (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Miconazole (Compound)
Diclofenac (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Miconazole
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Miconazole
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Diclofenac may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Miconazole |
DB00526 | DB10316 | 1,555 | 334 | [
"DDInter1355",
"DDInter1248"
] | Oxaliplatin | Mumps virus strain B level jeryl lynn live antigen | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1555,
25,
334
]
],
[
[
1555,
24,
594
],
[
594,
25,
334
]
],
[
[
1555,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1555,
25,
908
],
[
908,
25,
334
]
],
[
[
1555,
63,
589
],
[
589,
25,
334
]
],
[
[
1555,
24,
1619
],
[
1619,
64,
334
]
],
[
[
1555,
25,
1259
],
[
1259,
64,
334
]
],
[
[
1555,
24,
594
],
[
594,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1555,
64,
1057
],
[
1057,
25,
1042
],
[
1042,
24,
334
]
],
[
[
1555,
25,
908
],
[
908,
64,
1042
],
[
1042,
24,
334
]
]
] | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
]
] | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Oxaliplatin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen |
DB00726 | DB06694 | 1,164 | 31 | [
"DDInter1876",
"DDInter1952"
] | Trimipramine | Xylometazoline (nasal) | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
1164,
24,
31
]
],
[
[
1164,
6,
5214
],
[
5214,
45,
31
]
],
[
[
1164,
24,
144
],
[
144,
63,
31
]
],
[
[
1164,
24,
1148
],
[
1148,
24,
31
]
],
[
[
1164,
1,
1237
],
[
1237,
24,
31
]
],
[
[
1164,
25,
1629
],
[
1629,
63,
31
]
],
[
[
1164,
37,
247
],
[
247,
64,
31
]
],
[
[
1164,
6,
5214
],
[
5214,
45,
223
],
[
223,
40,
31
]
],
[
[
1164,
24,
144
],
[
144,
63,
87
],
[
87,
24,
31
]
],
[
[
1164,
1,
1237
],
[
1237,
6,
5372
],
[
5372,
45,
31
]
]
] | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Oxymetazoline"
],
[
"Oxymetazoline",
"{u} (Compound) resembles {v} (Compound)",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",
"Xylometazoline"
]
]
] | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Xylometazoline (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Trimipramine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Xylometazoline
Trimipramine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Oxymetazoline (Compound) and Oxymetazoline (Compound) resembles Xylometazoline (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Trimipramine (Compound) resembles Clomipramine (Compound) and Clomipramine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Xylometazoline (Compound) |
DB00687 | DB08868 | 870 | 1,011 | [
"DDInter747",
"DDInter737"
] | Fludrocortisone | Fingolimod | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
870,
25,
1011
]
],
[
[
870,
21,
28714
],
[
28714,
60,
1011
]
],
[
[
870,
24,
61
],
[
61,
24,
1011
]
],
[
[
870,
63,
751
],
[
751,
24,
1011
]
],
[
[
870,
24,
748
],
[
748,
63,
1011
]
],
[
[
870,
23,
480
],
[
480,
24,
1011
]
],
[
[
870,
23,
1032
],
[
1032,
63,
1011
]
],
[
[
870,
24,
1592
],
[
1592,
25,
1011
]
],
[
[
870,
25,
976
],
[
976,
64,
1011
]
],
[
[
870,
64,
1066
],
[
1066,
25,
1011
]
]
] | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Fludrocortisone (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fingolimod (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may lead to a major life threatening interaction when taken with Fingolimod
Fludrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod
Fludrocortisone may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Fingolimod |
DB01105 | DB09098 | 222 | 98 | [
"DDInter1665",
"DDInter1700"
] | Sibutramine | Somatrem | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
222,
24,
98
]
],
[
[
222,
24,
1671
],
[
1671,
24,
98
]
],
[
[
222,
23,
159
],
[
159,
63,
98
]
],
[
[
222,
23,
609
],
[
609,
24,
98
]
],
[
[
222,
63,
1300
],
[
1300,
24,
98
]
],
[
[
222,
24,
1580
],
[
1580,
63,
98
]
],
[
[
222,
64,
1454
],
[
1454,
24,
98
]
],
[
[
222,
25,
318
],
[
318,
24,
98
]
],
[
[
222,
62,
1091
],
[
1091,
24,
98
]
],
[
[
222,
24,
879
],
[
879,
25,
98
]
]
] | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
],
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
],
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
]
] | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may lead to a major life threatening interaction when taken with Sufentanil and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone and Lumateperone may lead to a major life threatening interaction when taken with Somatrem |
DB01115 | DB06691 | 336 | 849 | [
"DDInter1291",
"DDInter1155"
] | Nifedipine | Mepyramine | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
336,
24,
849
]
],
[
[
336,
6,
12523
],
[
12523,
45,
849
]
],
[
[
336,
63,
770
],
[
770,
24,
849
]
],
[
[
336,
40,
1428
],
[
1428,
24,
849
]
],
[
[
336,
24,
412
],
[
412,
63,
849
]
],
[
[
336,
1,
1081
],
[
1081,
24,
849
]
],
[
[
336,
24,
1053
],
[
1053,
24,
849
]
],
[
[
336,
6,
12523
],
[
12523,
45,
23
],
[
23,
40,
849
]
],
[
[
336,
63,
770
],
[
770,
63,
1594
],
[
1594,
24,
849
]
],
[
[
336,
63,
1648
],
[
1648,
24,
1594
],
[
1594,
24,
849
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Nifedipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Mepyramine (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00327 | DB00889 | 421 | 1,133 | [
"DDInter890",
"DDInter840"
] | Hydromorphone | Granisetron | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
421,
24,
1133
]
],
[
[
421,
24,
19
],
[
19,
40,
1133
]
],
[
[
421,
24,
85
],
[
85,
1,
1133
]
],
[
[
421,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
421,
21,
28851
],
[
28851,
60,
1133
]
],
[
[
421,
24,
820
],
[
820,
63,
1133
]
],
[
[
421,
1,
314
],
[
314,
24,
1133
]
],
[
[
421,
1,
560
],
[
560,
63,
1133
]
],
[
[
421,
24,
543
],
[
543,
24,
1133
]
],
[
[
421,
64,
475
],
[
475,
24,
1133
]
]
] | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} (Compound) resembles {v} (Compound)",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} (Compound) resembles {v} (Compound)",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatic enzyme increased"
],
[
"Hepatic enzyme increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
]
] | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compound)
Hydromorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Hydromorphone (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Granisetron (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Hydromorphone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron |
DB00584 | DB01261 | 610 | 170 | [
"DDInter638",
"DDInter1679"
] | Enalapril | Sitagliptin | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
610,
24,
170
]
],
[
[
610,
6,
8374
],
[
8374,
45,
170
]
],
[
[
610,
18,
3671
],
[
3671,
57,
170
]
],
[
[
610,
21,
28850
],
[
28850,
60,
170
]
],
[
[
610,
24,
708
],
[
708,
63,
170
]
],
[
[
610,
40,
1638
],
[
1638,
24,
170
]
],
[
[
610,
63,
1179
],
[
1179,
24,
170
]
],
[
[
610,
24,
167
],
[
167,
24,
170
]
],
[
[
610,
25,
1510
],
[
1510,
63,
170
]
],
[
[
610,
1,
664
],
[
664,
24,
170
]
]
] | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} (Compound) downregulates {v} (Gene)",
"CD40"
],
[
"CD40",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
]
] | Enalapril (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Enalapril (Compound) downregulates CD40 (Gene) and CD40 (Gene) is downregulated by Sitagliptin (Compound)
Enalapril (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Enalapril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Enalapril may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Enalapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin |
DB08912 | DB09083 | 1,040 | 880 | [
"DDInter462",
"DDInter996"
] | Dabrafenib | Ivabradine | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects. | Moderate | 1 | [
[
[
1040,
24,
880
]
],
[
[
1040,
63,
1478
],
[
1478,
24,
880
]
],
[
[
1040,
24,
159
],
[
159,
63,
880
]
],
[
[
1040,
24,
951
],
[
951,
24,
880
]
],
[
[
1040,
62,
1101
],
[
1101,
24,
880
]
],
[
[
1040,
25,
1476
],
[
1476,
63,
880
]
],
[
[
1040,
63,
39
],
[
39,
25,
880
]
],
[
[
1040,
24,
351
],
[
351,
64,
880
]
],
[
[
1040,
25,
124
],
[
124,
64,
880
]
],
[
[
1040,
24,
384
],
[
384,
25,
880
]
]
] | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
]
] | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dabrafenib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivabradine
Dabrafenib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivabradine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ivabradine |
DB01097 | DB13915 | 1,377 | 689 | [
"DDInter1033",
"DDInter146"
] | Leflunomide | Axicabtagene ciloleucel | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill cancer cells, and are infused back into the patient. Each dose of axicabtagene ciloleucel represent the patient's genetically modified T-cells. The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR can produce cytokines that efficiently kill leukemic cells _in vitro_. Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018. | Major | 2 | [
[
[
1377,
25,
689
]
],
[
[
1377,
64,
599
],
[
599,
24,
689
]
],
[
[
1377,
25,
270
],
[
270,
24,
689
]
],
[
[
1377,
24,
1430
],
[
1430,
24,
689
]
],
[
[
1377,
63,
597
],
[
597,
24,
689
]
],
[
[
1377,
25,
976
],
[
976,
25,
689
]
],
[
[
1377,
64,
1066
],
[
1066,
25,
689
]
],
[
[
1377,
25,
676
],
[
676,
64,
689
]
],
[
[
1377,
64,
599
],
[
599,
24,
810
],
[
810,
24,
689
]
],
[
[
1377,
64,
66
],
[
66,
63,
599
],
[
599,
24,
689
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
]
] | Leflunomide may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Leflunomide may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel |
DB08860 | DB08865 | 788 | 1,593 | [
"DDInter1479",
"DDInter448"
] | Pitavastatin | Crizotinib | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
788,
24,
1593
]
],
[
[
788,
18,
1748
],
[
1748,
45,
1593
]
],
[
[
788,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
788,
7,
7580
],
[
7580,
45,
1593
]
],
[
[
788,
7,
7972
],
[
7972,
46,
1593
]
],
[
[
788,
18,
17537
],
[
17537,
46,
1593
]
],
[
[
788,
34,
8559
],
[
8559,
46,
1593
]
],
[
[
788,
18,
6423
],
[
6423,
57,
1593
]
],
[
[
788,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
788,
24,
466
],
[
466,
62,
1593
]
]
] | [
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) downregulates {v} (Gene)",
"IGF1R"
],
[
"IGF1R",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) upregulates {v} (Gene)",
"TESK1"
],
[
"TESK1",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) upregulates {v} (Gene)",
"COL11A1"
],
[
"COL11A1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) downregulates {v} (Gene)",
"USP6NL"
],
[
"USP6NL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene)",
"HMGCR"
],
[
"HMGCR",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) downregulates {v} (Gene)",
"ABCE1"
],
[
"ABCE1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
]
] | Pitavastatin (Compound) downregulates IGF1R (Gene) and IGF1R (Gene) is bound by Crizotinib (Compound)
Pitavastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Pitavastatin (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is bound by Crizotinib (Compound)
Pitavastatin (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Pitavastatin (Compound) downregulates USP6NL (Gene) and USP6NL (Gene) is upregulated by Crizotinib (Compound)
Pitavastatin (Compound) binds HMGCR (Gene) and Pitavastatin (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Crizotinib (Compound)
Pitavastatin (Compound) downregulates ABCE1 (Gene) and ABCE1 (Gene) is downregulated by Crizotinib (Compound)
Pitavastatin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Crizotinib |
DB09312 | DB00163 | 967 | 1,461 | [
"DDInter106",
"DDInter1943"
] | Antithymocyte immunoglobulin (rabbit) | Vitamin E | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Minor | 0 | [
[
[
967,
23,
1461
]
],
[
[
967,
64,
581
],
[
581,
23,
1461
]
],
[
[
967,
25,
1510
],
[
1510,
62,
1461
]
],
[
[
967,
63,
66
],
[
66,
23,
1461
]
],
[
[
967,
63,
1683
],
[
1683,
62,
1461
]
],
[
[
967,
24,
270
],
[
270,
62,
1461
]
],
[
[
967,
64,
908
],
[
908,
62,
1461
]
],
[
[
967,
64,
1064
],
[
1064,
63,
1461
]
],
[
[
967,
64,
581
],
[
581,
25,
76
],
[
76,
62,
1461
]
],
[
[
967,
25,
1510
],
[
1510,
25,
76
],
[
76,
62,
1461
]
]
] | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
]
] | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E |
DB08904 | DB11627 | 375 | 1,367 | [
"DDInter342",
"DDInter860"
] | Certolizumab pegol | Hepatitis B Vaccine (Recombinant) | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
375,
24,
1367
]
],
[
[
375,
64,
1083
],
[
1083,
24,
1367
]
],
[
[
375,
25,
1480
],
[
1480,
24,
1367
]
],
[
[
375,
25,
119
],
[
119,
63,
1367
]
],
[
[
375,
63,
66
],
[
66,
24,
1367
]
],
[
[
375,
64,
1083
],
[
1083,
75,
1064
],
[
1064,
24,
1367
]
],
[
[
375,
64,
1648
],
[
1648,
24,
1560
],
[
1560,
24,
1367
]
],
[
[
375,
64,
1560
],
[
1560,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
375,
64,
1064
],
[
1064,
36,
1083
],
[
1083,
24,
1367
]
],
[
[
375,
25,
1480
],
[
1480,
64,
1064
],
[
1064,
24,
1367
]
]
] | [
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
]
] | Certolizumab pegol may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB00398 | DB11853 | 79 | 230 | [
"DDInter1702",
"DDInter1577"
] | Sorafenib | Relugolix | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. | Moderate | 1 | [
[
[
79,
24,
230
]
],
[
[
79,
24,
129
],
[
129,
23,
230
]
],
[
[
79,
23,
112
],
[
112,
23,
230
]
],
[
[
79,
63,
1101
],
[
1101,
23,
230
]
],
[
[
79,
24,
1476
],
[
1476,
62,
230
]
],
[
[
79,
24,
480
],
[
480,
24,
230
]
],
[
[
79,
25,
1456
],
[
1456,
24,
230
]
],
[
[
79,
63,
1494
],
[
1494,
24,
230
]
],
[
[
79,
24,
1017
],
[
1017,
63,
230
]
],
[
[
79,
24,
578
],
[
578,
25,
230
]
]
] | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
]
] | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Sorafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Relugolix |
DB00687 | DB01390 | 870 | 1,117 | [
"DDInter747",
"DDInter1683"
] | Fludrocortisone | Sodium bicarbonate | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
870,
23,
1117
]
],
[
[
870,
21,
28778
],
[
28778,
60,
1117
]
],
[
[
870,
1,
1220
],
[
1220,
23,
1117
]
],
[
[
870,
62,
1018
],
[
1018,
23,
1117
]
],
[
[
870,
63,
1638
],
[
1638,
23,
1117
]
],
[
[
870,
24,
954
],
[
954,
23,
1117
]
],
[
[
870,
24,
1482
],
[
1482,
62,
1117
]
],
[
[
870,
24,
972
],
[
972,
63,
1117
]
],
[
[
870,
24,
1213
],
[
1213,
24,
1117
]
],
[
[
870,
63,
362
],
[
362,
24,
1117
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
]
] | Fludrocortisone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Sodium bicarbonate (Compound)
Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate |
DB00333 | DB09020 | 576 | 28 | [
"DDInter1166",
"DDInter212"
] | Methadone | Bisacodyl | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric toxicity compared to other opioids (due to a lack of active metabolites), minimal accumulation in renal failure, good bioavailability, low cost, and a long duration of action.[F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
576,
24,
28
]
],
[
[
576,
24,
662
],
[
662,
1,
28
]
],
[
[
576,
24,
128
],
[
128,
40,
28
]
],
[
[
576,
21,
28809
],
[
28809,
60,
28
]
],
[
[
576,
25,
823
],
[
823,
63,
28
]
],
[
[
576,
25,
1250
],
[
1250,
24,
28
]
],
[
[
576,
64,
702
],
[
702,
24,
28
]
],
[
[
576,
1,
847
],
[
847,
24,
28
]
],
[
[
576,
24,
355
],
[
355,
24,
28
]
],
[
[
576,
24,
286
],
[
286,
63,
28
]
]
] | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
]
] | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles Bisacodyl (Compound)
Methadone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Methadone may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methadone may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methadone may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methadone (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl |
DB09498 | DB15719 | 810 | 487 | [
"DDInter1715",
"DDInter171"
] | Strontium chloride Sr-89 | Belantamab mafodotin | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect. | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. | Moderate | 1 | [
[
[
810,
24,
487
]
],
[
[
810,
63,
4
],
[
4,
24,
487
]
],
[
[
810,
24,
738
],
[
738,
24,
487
]
],
[
[
810,
63,
976
],
[
976,
25,
487
]
],
[
[
810,
24,
1259
],
[
1259,
25,
487
]
],
[
[
810,
64,
1064
],
[
1064,
25,
487
]
],
[
[
810,
63,
4
],
[
4,
63,
440
],
[
440,
24,
487
]
],
[
[
810,
63,
597
],
[
597,
24,
4
],
[
4,
24,
487
]
],
[
[
810,
24,
738
],
[
738,
63,
440
],
[
440,
24,
487
]
],
[
[
810,
63,
976
],
[
976,
64,
259
],
[
259,
24,
487
]
]
] | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
]
] | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Belantamab mafodotin
Strontium chloride Sr-89 may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin |
DB01115 | DB01132 | 336 | 1,130 | [
"DDInter1291",
"DDInter1472"
] | Nifedipine | Pioglitazone | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus. | Minor | 0 | [
[
[
336,
23,
1130
]
],
[
[
336,
6,
12523
],
[
12523,
45,
1130
]
],
[
[
336,
7,
1870
],
[
1870,
46,
1130
]
],
[
[
336,
21,
28778
],
[
28778,
60,
1130
]
],
[
[
336,
63,
11
],
[
11,
24,
1130
]
],
[
[
336,
24,
214
],
[
214,
63,
1130
]
],
[
[
336,
25,
1604
],
[
1604,
63,
1130
]
],
[
[
336,
6,
12523
],
[
12523,
45,
23
],
[
23,
40,
1130
]
],
[
[
336,
6,
8374
],
[
8374,
48,
11640
],
[
11640,
44,
1130
]
],
[
[
336,
7,
1870
],
[
1870,
46,
23
],
[
23,
40,
1130
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) upregulates {v} (Gene)",
"MYC"
],
[
"MYC",
"{u} (Gene) is upregulated by {v} (Compound)",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} (Compound) resembles {v} (Compound)",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is associated with {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Compound)",
"Pioglitazone"
]
],
[
[
"Nifedipine",
"{u} (Compound) upregulates {v} (Gene)",
"MYC"
],
[
"MYC",
"{u} (Gene) is upregulated by {v} (Compound)",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} (Compound) resembles {v} (Compound)",
"Pioglitazone"
]
]
] | Nifedipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Nifedipine (Compound) upregulates MYC (Gene) and MYC (Gene) is upregulated by Pioglitazone (Compound)
Nifedipine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Pioglitazone (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Nifedipine may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Nifedipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Pioglitazone (Compound)
Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Pioglitazone (Compound)
Nifedipine (Compound) upregulates MYC (Gene) and MYC (Gene) is upregulated by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Pioglitazone (Compound) |
DB00197 | DB09118 | 1,324 | 1,580 | [
"DDInter1881",
"DDInter1711"
] | Troglitazone | Stiripentol | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
1324,
24,
1580
]
],
[
[
1324,
24,
466
],
[
466,
62,
1580
]
],
[
[
1324,
24,
1409
],
[
1409,
24,
1580
]
],
[
[
1324,
24,
283
],
[
283,
63,
1580
]
],
[
[
1324,
63,
168
],
[
168,
24,
1580
]
],
[
[
1324,
23,
608
],
[
608,
24,
1580
]
],
[
[
1324,
25,
1510
],
[
1510,
24,
1580
]
],
[
[
1324,
24,
1456
],
[
1456,
64,
1580
]
],
[
[
1324,
24,
1135
],
[
1135,
25,
1580
]
],
[
[
1324,
24,
466
],
[
466,
62,
283
],
[
283,
63,
1580
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Troglitazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may lead to a major life threatening interaction when taken with Stiripentol
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol |
DB00405 | DB00418 | 128 | 536 | [
"DDInter517",
"DDInter1650"
] | Dexbrompheniramine | Secobarbital | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Moderate | 1 | [
[
[
128,
24,
536
]
],
[
[
128,
63,
1023
],
[
1023,
1,
536
]
],
[
[
128,
24,
697
],
[
697,
1,
536
]
],
[
[
128,
24,
682
],
[
682,
40,
536
]
],
[
[
128,
24,
1233
],
[
1233,
63,
536
]
],
[
[
128,
74,
1594
],
[
1594,
24,
536
]
],
[
[
128,
63,
999
],
[
999,
24,
536
]
],
[
[
128,
63,
475
],
[
475,
25,
536
]
],
[
[
128,
63,
1023
],
[
1023,
1,
773
],
[
773,
1,
536
]
],
[
[
128,
24,
697
],
[
697,
40,
773
],
[
773,
1,
536
]
]
] | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Amobarbital"
],
[
"Amobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Amobarbital"
],
[
"Amobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
]
] | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Secobarbital (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thiopental and Thiopental (Compound) resembles Secobarbital (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Secobarbital
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound) |
DB00425 | DB14568 | 558 | 982 | [
"DDInter1970",
"DDInter1000"
] | Zolpidem | Ivosidenib | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
558,
24,
982
]
],
[
[
558,
63,
1101
],
[
1101,
23,
982
]
],
[
[
558,
24,
770
],
[
770,
24,
982
]
],
[
[
558,
24,
159
],
[
159,
63,
982
]
],
[
[
558,
24,
1297
],
[
1297,
25,
982
]
],
[
[
558,
63,
600
],
[
600,
25,
982
]
],
[
[
558,
63,
1101
],
[
1101,
23,
271
],
[
271,
23,
982
]
],
[
[
558,
24,
770
],
[
770,
63,
112
],
[
112,
23,
982
]
],
[
[
558,
24,
1478
],
[
1478,
23,
271
],
[
271,
23,
982
]
],
[
[
558,
24,
1476
],
[
1476,
62,
168
],
[
168,
23,
982
]
]
] | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
]
] | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib |
DB09054 | DB09073 | 384 | 951 | [
"DDInter905",
"DDInter1379"
] | Idelalisib | Palbociclib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Major | 2 | [
[
[
384,
25,
951
]
],
[
[
384,
23,
907
],
[
907,
62,
951
]
],
[
[
384,
62,
318
],
[
318,
23,
951
]
],
[
[
384,
24,
496
],
[
496,
63,
951
]
],
[
[
384,
25,
1476
],
[
1476,
63,
951
]
],
[
[
384,
63,
1454
],
[
1454,
24,
951
]
],
[
[
384,
64,
467
],
[
467,
24,
951
]
],
[
[
384,
62,
555
],
[
555,
24,
951
]
],
[
[
384,
63,
1091
],
[
1091,
25,
951
]
],
[
[
384,
64,
1066
],
[
1066,
25,
951
]
]
] | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
]
] | Idelalisib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Idelalisib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Idelalisib may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Netupitant and Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Palbociclib
Idelalisib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Palbociclib |
DB00938 | DB01254 | 455 | 1,213 | [
"DDInter1635",
"DDInter484"
] | Salmeterol | Dasatinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
455,
24,
1213
]
],
[
[
455,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
455,
7,
1986
],
[
1986,
46,
1213
]
],
[
[
455,
18,
2284
],
[
2284,
57,
1213
]
],
[
[
455,
6,
3576
],
[
3576,
57,
1213
]
],
[
[
455,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
455,
63,
1133
],
[
1133,
24,
1213
]
],
[
[
455,
24,
1619
],
[
1619,
63,
1213
]
],
[
[
455,
24,
688
],
[
688,
24,
1213
]
],
[
[
455,
62,
891
],
[
891,
24,
1213
]
]
] | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) downregulates {v} (Gene)",
"PRPF4"
],
[
"PRPF4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] | Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Salmeterol (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Dasatinib (Compound)
Salmeterol (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is downregulated by Dasatinib (Compound)
Salmeterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Dasatinib (Compound)
Salmeterol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB02546 | DB06203 | 137 | 1,002 | [
"DDInter1947",
"DDInter51"
] | Vorinostat | Alogliptin | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
137,
24,
1002
]
],
[
[
137,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
137,
21,
28966
],
[
28966,
60,
1002
]
],
[
[
137,
63,
176
],
[
176,
24,
1002
]
],
[
[
137,
24,
1296
],
[
1296,
63,
1002
]
],
[
[
137,
24,
1281
],
[
1281,
6,
4405
],
[
4405,
45,
1002
]
],
[
[
137,
21,
28966
],
[
28966,
60,
1281
],
[
1281,
40,
1002
]
],
[
[
137,
63,
176
],
[
176,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
137,
24,
1296
],
[
1296,
63,
1281
],
[
1281,
40,
1002
]
],
[
[
137,
21,
28966
],
[
28966,
60,
504
],
[
504,
24,
1002
]
]
] | [
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} (Compound) causes {v} (Side Effect)",
"Upper respiratory tract infection"
],
[
"Upper respiratory tract infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) binds {v} (Gene)",
"DPP4"
],
[
"DPP4",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} (Compound) causes {v} (Side Effect)",
"Upper respiratory tract infection"
],
[
"Upper respiratory tract infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Vorinostat",
"{u} (Compound) causes {v} (Side Effect)",
"Upper respiratory tract infection"
],
[
"Upper respiratory tract infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
]
] | Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Vorinostat (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Alogliptin (Compound)
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) binds DPP4 (Gene) and DPP4 (Gene) is bound by Alogliptin (Compound)
Vorinostat (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Vorinostat (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin |
DB00559 | DB11828 | 152 | 1,406 | [
"DDInter223",
"DDInter1281"
] | Bosentan | Neratinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
152,
25,
1406
]
],
[
[
152,
24,
1135
],
[
1135,
23,
1406
]
],
[
[
152,
24,
392
],
[
392,
24,
1406
]
],
[
[
152,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
152,
63,
1195
],
[
1195,
24,
1406
]
],
[
[
152,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
152,
24,
1593
],
[
1593,
25,
1406
]
],
[
[
152,
25,
283
],
[
283,
64,
1406
]
],
[
[
152,
25,
760
],
[
760,
25,
1406
]
],
[
[
152,
63,
600
],
[
600,
25,
1406
]
]
] | [
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Bosentan may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Bosentan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Neratinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Neratinib |
DB04953 | DB12245 | 495 | 823 | [
"DDInter708",
"DDInter1863"
] | Ezogabine | Triclabendazole | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
495,
24,
823
]
],
[
[
495,
62,
112
],
[
112,
23,
823
]
],
[
[
495,
63,
1010
],
[
1010,
24,
823
]
],
[
[
495,
24,
28
],
[
28,
24,
823
]
],
[
[
495,
24,
1619
],
[
1619,
63,
823
]
],
[
[
495,
25,
868
],
[
868,
25,
823
]
],
[
[
495,
64,
702
],
[
702,
25,
823
]
],
[
[
495,
25,
982
],
[
982,
64,
823
]
],
[
[
495,
62,
112
],
[
112,
23,
1247
],
[
1247,
23,
823
]
],
[
[
495,
63,
1010
],
[
1010,
23,
1247
],
[
1247,
23,
823
]
]
] | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
]
] | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ezogabine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Ezogabine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Ezogabine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Triclabendazole
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole |
DB00026 | DB01068 | 1,184 | 1,565 | [
"DDInter94",
"DDInter411"
] | Anakinra | Clonazepam | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse.[FDA Label][L5572,F3763,F3787,F3796] | Moderate | 1 | [
[
[
1184,
24,
1565
]
],
[
[
1184,
24,
1382
],
[
1382,
1,
1565
]
],
[
[
1184,
24,
1031
],
[
1031,
23,
1565
]
],
[
[
1184,
24,
259
],
[
259,
63,
1565
]
],
[
[
1184,
24,
1101
],
[
1101,
24,
1565
]
],
[
[
1184,
64,
1057
],
[
1057,
24,
1565
]
],
[
[
1184,
25,
980
],
[
980,
63,
1565
]
],
[
[
1184,
25,
581
],
[
581,
24,
1565
]
],
[
[
1184,
24,
1382
],
[
1382,
1,
406
],
[
406,
40,
1565
]
],
[
[
1184,
24,
523
],
[
523,
40,
11311
],
[
11311,
1,
1565
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
],
[
"Diazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
],
[
"Nitrazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clonazepam (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Clonazepam
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Anakinra may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Anakinra may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Clonazepam (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Nitrazepam (Compound) and Nitrazepam (Compound) resembles Clonazepam (Compound) |
DB00620 | DB00867 | 175 | 1,052 | [
"DDInter1855",
"DDInter1606"
] | Triamcinolone | Ritodrine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Adrenergic beta-agonist used to control premature labor. | Minor | 0 | [
[
[
175,
23,
1052
]
],
[
[
175,
63,
1523
],
[
1523,
40,
1052
]
],
[
[
175,
40,
1351
],
[
1351,
23,
1052
]
],
[
[
175,
40,
1220
],
[
1220,
62,
1052
]
],
[
[
175,
1,
617
],
[
617,
62,
1052
]
],
[
[
175,
23,
1148
],
[
1148,
63,
1052
]
],
[
[
175,
24,
135
],
[
135,
63,
1052
]
],
[
[
175,
63,
245
],
[
245,
24,
1052
]
],
[
[
175,
24,
1144
],
[
1144,
24,
1052
]
],
[
[
175,
25,
609
],
[
609,
63,
1052
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ritodrine (Compound)
Triamcinolone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Triamcinolone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine |
DB00330 | DB00773 | 238 | 896 | [
"DDInter689",
"DDInter702"
] | Ethambutol | Etoposide | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. Ethambutol was granted FDA approval on 6 November 1967. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
238,
24,
896
]
],
[
[
238,
21,
28681
],
[
28681,
60,
896
]
],
[
[
238,
24,
147
],
[
147,
23,
896
]
],
[
[
238,
24,
310
],
[
310,
63,
896
]
],
[
[
238,
24,
322
],
[
322,
24,
896
]
],
[
[
238,
63,
367
],
[
367,
24,
896
]
],
[
[
238,
63,
1057
],
[
1057,
25,
896
]
],
[
[
238,
24,
375
],
[
375,
64,
896
]
],
[
[
238,
25,
1510
],
[
1510,
64,
896
]
],
[
[
238,
24,
63
],
[
63,
35,
896
]
]
] | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
]
] | Ethambutol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Etoposide
Ethambutol may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Etoposide
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide (Compound) resembles Etoposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Etoposide |
DB01250 | DB01265 | 712 | 1,477 | [
"DDInter1334",
"DDInter1757"
] | Olsalazine | Telbivudine | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene. Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
712,
24,
1477
]
],
[
[
712,
63,
485
],
[
485,
24,
1477
]
],
[
[
712,
64,
629
],
[
629,
24,
1477
]
],
[
[
712,
1,
50
],
[
50,
24,
1477
]
],
[
[
712,
63,
485
],
[
485,
63,
139
],
[
139,
1,
1477
]
],
[
[
712,
63,
1441
],
[
1441,
21,
28719
],
[
28719,
60,
1477
]
],
[
[
712,
64,
629
],
[
629,
63,
139
],
[
139,
1,
1477
]
],
[
[
712,
1,
50
],
[
50,
63,
485
],
[
485,
24,
1477
]
],
[
[
712,
1,
11346
],
[
11346,
21,
28757
],
[
28757,
60,
1477
]
],
[
[
712,
64,
629
],
[
629,
21,
28745
],
[
28745,
60,
1477
]
]
] | [
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
]
]
] | Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Olsalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Telbivudine (Compound)
Olsalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Olsalazine (Compound) resembles Magnesium salicylate (Compound) and Magnesium salicylate (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Telbivudine (Compound)
Olsalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound) |
DB00227 | DB09098 | 1,463 | 98 | [
"DDInter1098",
"DDInter1700"
] | Lovastatin | Somatrem | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
1463,
24,
98
]
],
[
[
1463,
63,
168
],
[
168,
23,
98
]
],
[
[
1463,
24,
159
],
[
159,
63,
98
]
],
[
[
1463,
25,
609
],
[
609,
24,
98
]
],
[
[
1463,
24,
63
],
[
63,
24,
98
]
],
[
[
1463,
35,
467
],
[
467,
24,
98
]
],
[
[
1463,
63,
837
],
[
837,
24,
98
]
],
[
[
1463,
23,
123
],
[
123,
24,
98
]
],
[
[
1463,
24,
1101
],
[
1101,
25,
98
]
],
[
[
1463,
63,
168
],
[
168,
24,
671
],
[
671,
24,
98
]
]
] | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin (Compound) resembles Simvastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB00011 | DB01235 | 1,451 | 1,191 | [
"DDInter944",
"DDInter1054"
] | Interferon alfa-n1 | Levodopa | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. | Moderate | 1 | [
[
[
1451,
24,
1191
]
],
[
[
1451,
24,
63
],
[
63,
24,
1191
]
],
[
[
1451,
24,
148
],
[
148,
63,
1191
]
],
[
[
1451,
25,
1377
],
[
1377,
24,
1191
]
],
[
[
1451,
25,
1510
],
[
1510,
63,
1191
]
],
[
[
1451,
63,
491
],
[
491,
24,
1191
]
],
[
[
1451,
24,
63
],
[
63,
18,
10891
],
[
10891,
45,
1191
]
],
[
[
1451,
24,
148
],
[
148,
63,
63
],
[
63,
24,
1191
]
],
[
[
1451,
24,
458
],
[
458,
21,
28936
],
[
28936,
60,
1191
]
],
[
[
1451,
24,
896
],
[
896,
24,
1307
],
[
1307,
40,
1191
]
]
] | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} (Compound) downregulates {v} (Gene)",
"PSIP1"
],
[
"PSIP1",
"{u} (Gene) is bound by {v} (Compound)",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
"Tinidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levodopa"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
]
]
] | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide (Compound) downregulates PSIP1 (Gene) and PSIP1 (Gene) is bound by Levodopa (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Levodopa (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound) |
DB01229 | DB08913 | 973 | 1,186 | [
"DDInter1378",
"DDInter1561"
] | Paclitaxel (protein-bound) | Radium Ra 223 dichloride | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. | Moderate | 1 | [
[
[
973,
24,
1186
]
],
[
[
973,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
973,
63,
134
],
[
134,
24,
1186
]
],
[
[
973,
24,
1491
],
[
1491,
24,
1186
]
],
[
[
973,
24,
1619
],
[
1619,
63,
1186
]
],
[
[
973,
64,
1377
],
[
1377,
24,
1186
]
],
[
[
973,
25,
1510
],
[
1510,
24,
1186
]
],
[
[
973,
25,
1259
],
[
1259,
63,
1186
]
],
[
[
973,
24,
1374
],
[
1374,
25,
1186
]
],
[
[
973,
21,
28872
],
[
28872,
60,
134
],
[
134,
24,
1186
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may lead to a major life threatening interaction when taken with Radium Ra 223 dichloride
Paclitaxel (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.